Walden University

ScholarWorks
Walden Dissertations and Doctoral Studies

Walden Dissertations and Doctoral Studies
Collection

2021

Development and Implementation Strategies for Open Innovation
Pharmaceutical R&D Projects
John A. Maher
Walden University

Follow this and additional works at: https://scholarworks.waldenu.edu/dissertations
Part of the Entrepreneurial and Small Business Operations Commons
This Dissertation is brought to you for free and open access by the Walden Dissertations and Doctoral Studies
Collection at ScholarWorks. It has been accepted for inclusion in Walden Dissertations and Doctoral Studies by an
authorized administrator of ScholarWorks. For more information, please contact ScholarWorks@waldenu.edu.

Walden University
College of Management and Technology

This is to certify that the doctoral study by
John A. Maher

has been found to be complete and satisfactory in all respects,
and that any and all revisions required by
the review committee have been made.
Review Committee
Dr. Warren Lesser, Committee Chairperson, Doctor of Business Administration Faculty
Dr. Matasha Murrelljones, Committee Member, Doctor of Business Administration Faculty
Dr. Richard Johnson, University Reviewer, Doctor of Business Administration Faculty

Chief Academic Officer and Provost
Sue Subocz, Ph.D.

Walden University
2021

Abstract
Development and Implementation Strategies for Open Innovation Pharmaceutical
R&D Projects
by
John A. Maher
MBA, Hagan School of Business, Iona College, 2002
MBA, Hagan School of Business, Iona College, 2000
MS, Biotechnology, Manhattan College, 1995
BS, Veterinary Technology, Mercy College, 1985

Doctoral Study Submitted in Partial Fulfillment
of the Requirements for the Degree of
Doctor of Business Administration

Walden University
May 2021

Abstract
US pharmaceutical company leaders who lack strategies for developing and
implementing open innovation (OI) Research & Development (R&D) projects may
experience weakened competitive positioning in the industry. Grounded in the open
innovation capability framework, the purpose of this qualitative single case study was to
explore implementation strategies R&D directors use to implement OI R&D projects in
the US. Participants were five US pharmaceutical R&D directors from a single
organization. Data were collected using semistructured interviews, public information,
and OI literature and analyzed using Castleberry and Nolen’s five-step model. Four
themes emerged: roles and responsibilities, business and OI strategy alignment,
leadership attention, and OI decision-making. A key recommendation for pharmaceutical
R&D directors is to develop a clear OI strategy aligned with the business strategy and
assemble two teams, a search and evaluation team and an alliance management team, to
help identify and assimilate OI projects. Positive social change implications include the
potential for pharmaceutical leaders using more efficient methods of R&D, resulting in
the discovery and development of novel therapeutics at a lower cost to patients, making it
more affordable to improve their quality of life.
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Section 1: Foundation of the Study
Background of the Problem
The US pharmaceutical industry supports over 3.4 million jobs across the US in
multiple industries and added an estimated $800 billion to the economy in 2015
(Muratoglu, 2017). It is a major contributor to the US economy and considered a
significant part of the global market (Lakdawalla, 2018). Downs & Velamuri (2016) said
over the last 60 years, inflation-adjusted research and development (R&D) expenditure
per molecule brought to market increased significantly. Despite billions of dollars the US
pharmaceutical industry collectively spends on R&D annually, the rate of novel therapy
output is declining versus historical productivity levels (Schumacher et al., 2016).
Problem Statement
US pharmaceutical company leaders experience challenges in terms of bringing
novel therapeutic agents through the R&D process to generate a sufficient return on
investment (ROI; DiMasi et al., 2020). OI strategies may increase the net present value of
projects by 70% compared to closed innovation projects (Chesbrough, 2017; Hosseini et
al., 2017). The general business problem is that US pharmaceutical company leaders’
failure to implement an OI business model may lead to less innovative and competitive
companies. The specific business problem is that some US pharmaceutical company
leaders lack strategies for developing and implementing OI R&D projects.
Purpose Statement
The purpose of this qualitative single case study was to explore strategies US
pharmaceutical company leaders used for developing and implementing OI R&D
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projects. The targeted population comprised five US pharmaceutical R&D directors in
one pharmaceutical firm that successfully used OI strategies to develop and implement
R&D drug development projects. The US pharmaceutical company is in the northeastern
region of the United States. My research findings may enhance US pharmaceutical
leaders’ capacities to increase ROI, decrease operational costs, and positively benefit
local communities through increased tax revenues and employment opportunities.
Furthermore, the efficient discovery and production of novel therapies may lead to a
better quality of life for many patients.
Nature of the Study
I used a qualitative single case study design to explore strategies five US
pharmaceutical company leaders used for developing and implementing successful OI
pharmaceutical R&D projects. Yin (2018) said a qualitative case study method can be
used for researching a contemporary topic and providing a detailed description of the unit
of analysis. A quantitative methodology was not appropriate for this exploratory study. It
is used to measure and analyze variables’ characteristics and relationships through
statistical analysis (Pessoa et al., 2019). Marshall and Rossman (2016) said the mixed
methods approach entails collecting both qualitative and quantitative data. I did not use a
mixed methods approach because the quantitative method was not necessary for
addressing the purpose of my study.
Soleimani et al. (2018) said researchers can use the case study design to
understand the nature and complexity of processes taking place in the context of a
phenomenon. Ethnographers focus on studying human society and culture (Merriam &
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Tisdell, 2016). The ethnography design was not appropriate for my research because I
was not studying culture or social groups. James (2018) said narrative inquiry consists of
in-depth interviews to collect, analyze, and interpret peoples’ life stories. The narrative
inquiry was not a suitable design because the intent of my study was not to provide a
summary of personal accounts of participants’ life stories related to events. The
phenomenology design was not appropriate because I was not researching the
fundamental nature of the meanings of human experiences with phenomena.
Phenomenologists are interested in people’s conscious experience of their everyday life
and social action (Smith, 2018). Therefore, a single-case design was the most appropriate
design to identify and explore strategies managers used to develop and implement OI
pharmaceutical R&D projects.
Research Question
What are the strategies that US pharmaceutical company leaders used to develop
and implement OI R&D projects?
Interview Questions
1. What strategies did you use to implement an OI business model for R&D
projects?
2. How did you identify new R&D projects to pursue using an OI strategy?
3. How did you decide which OI strategy to use for an OI R&D project?
4. What organizational issues did you consider when pursuing a given OI R&D
project?
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5. What organizational capabilities did you consider when pursuing a given OI
R&D project?
6. How did you decide which capabilities are important to implement an OI
R&D project?
7. How did you decide which employees should participate in the
implementation of OI R&D projects?
8. If your organizational culture supports OI R&D, describe how your culture
supports the implementation of OI R&D projects.
9. If the organizational culture supports OI, describe the strategies used to align
the organizational structure to support OI R&D projects.
10. What else can you tell me you did to enhance OI strategies?
Theoretical or Conceptual Framework
Since the inception of the OI theory, many researchers have studied the
phenomenon. Hosseini et al. (2017) developed an OI capability framework (OICF),
which is intended to serve as a foundation for assessing OI competencies of individuals in
an organization. Leaders could use the OICF as a guide for implementing OI in their
organization.
Hosseini et al. (2017) identified capabilities with similar characteristics and
qualities and grouped these capabilities into six factors: strategic alignment, governance,
methods, IT, people, and culture. The OICF is comprised of 23 capability areas stratified
among these six factors. The six factors identified are capabilities relevant to
implementing OI for R&D projects. I used the principal factors to verify the OICF’s
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relevance, and for understanding the strategies the participating pharmaceutical
organizations’ leaders used to select and implement OI R&D projects. I therefore
expected the OICF framework to be useful for understanding strategies organizational
leaders used to develop and implement OI in the context of the pharmaceutical industry.
Operational Definitions
Open innovation (OI): A distributed innovation process based on purposively
managed knowledge flows across organizational boundaries. OI provides insights into
how firms can harness inflows and outflows of knowledge to improve their innovation
success (Bogers et al., 2018).
Assumptions, Limitations, and Delimitations
In this subsection, I discuss the various assumptions, limitations, and
delimitations of my research. Investigators should plan the research process for the study.
Furthermore, assumptions, limitations, and delimitations of the study should be outlined.
Assumptions
Assumptions are facts the researcher assumes to be true (Marshall & Rossman,
2016). I made four assumptions in this study. My first assumption was that
pharmaceutical R&D directors provided adequate and truthful responses during
interviews. My second assumption was that pharmaceutical R&D directors shared
valuable rich information regarding their OI implementation strategies and experience.
My third assumption was that the OICF applied to the context of the pharmaceutical
industry. My final assumption was that a sample size of four pharmaceutical R&D
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directors experienced with implementing OI drug development projects was enough to
provide rich content for a single case study.
Limitations
One of the limitations of my study involved the choice of a single case study of
one pharmaceutical company located in the northeastern region of the US, which may not
represent all information possible from companies. Yin (2018) suggested single case
studies are exposed to limitations because there are more analytic benefits from having
multiple cases. Furthermore, the study findings may not apply to all US pharmaceutical
companies because of the limited geographical scope of the study.
Another limitation of my study was the participant sample size, because I
interviewed only five pharmaceutical R&D directors. The final limitation of my study
involves the use of semistructured interviews as my primary data collection method.
Bloomberg and Volpe (2019) suggested that not all interviewees are equally cooperative,
articulate, and perceptive. Many studies have limitations, so the investigators need to be
transparent regarding the limitations of their findings
Delimitations
Delimitations are limits imposed by the researchers’ study design and the
intentional choices the researcher makes to investigate the research problem (Bloomberg
& Volpe, 2019). The first delimitation of my study will be that the study participants are
from one pharmaceutical company in the northeastern region of the US A second
delimitation will be that the participants are pharmaceutical R&D directors with
experience implementing OI drug projects. A third delimitation of the study will be the

7
number of interviewees used to collect the data. Researchers should communicate the
boundaries of their research study by stating their exclusionary and inclusionary
decisions.
Significance of the Study
My study findings could be significant for leaders in pharmaceutical firms
seeking to use OI strategies to improve their firms’ competitive positions in the market.
Pharmaceutical leaders intending to implement an OI business model might be able to
use implementation strategies that I discovered through my research. Pharmaceutical
leaders may use the prospective framework to lead a more efficient and effective drug
development process for reducing the cost of developing drugs and increasing
pharmaceuticals firms’ efficacy.
Contribution to Business Practice
As pharmaceutical industry leaders struggle with controlling rising costs of drug
development, they search for more efficient strategies and methods for discovering and
developing novel therapeutics (Downs & Velamuri, 2016). Shaw (2017) said
pharmaceutical leaders are leveraging OI business models to improve their biomedical
innovation processes. However, proponents of OI typically encounter several barriers and
challenges; leaders of pharmaceutical firms need to develop strategies to implement OI.
If leaders of pharmaceutical firms had implementation frameworks for the OI business
model, pharmaceutical leaders could improve their chances of being successful. If my
research supports OICF relevance, pharmaceutical leaders may garner additional insights
to help implement OI and increase R&D projects’ success rates.
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Implications for Social Change
If my research findings are significant, pharmaceutical leaders implementing OI
may increase the efficiency of discovering and developing novel therapeutics. An
increase in the efficiency of discovering and developing novel therapeutics may lead to
cost-effective therapeutic remedies that provide a better quality of life for many patients,
and in some cases may save lives (Hunter et al., 2018). In addition, if the research bears
favorable results, pharmaceutical leaders who implement proposed strategies may
increase the viability of their organizations, which then may lead to employment
opportunities for members of local communities and better life quality for communities.
A Review of the Professional and Academic Literature
The purpose of this qualitative exploratory single case study is to explore
strategies that are critical to implementing an OI business model for pharmaceutical R&D
projects. I examine literature in this review related to OI in general as well as in relation
to the pharmaceutical industry and conceptual frameworks used to implement OI
strategies. My intention was to discover recent scholarly literature regarding specific
strategies for implementing OI in the pharmaceutical industry at the project level. I begin
the literature review with an overview of OI, followed by OI and the pharmaceutical
industry and a review of conceptual frameworks used to implement OI.
To construct the literature review, I obtained information through searches and
reviews of recent research regarding OI. I also accessed peer-reviewed literature by using
databases from the Walden University Library. The databases used to search for peerreviewed articles included Google Scholar, Business Source Complete, and
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ABI/INFORM Complete. The search included keywords open innovation, open
innovation AND pharmaceutical industry, open innovation AND implementation, open
innovation AND strategy, and open innovation AND projects. To construct the literature
review, I obtained information through searches and review of recent research around OI
and selected articles that were relevant to my area of study.
I searched the literature for peer-reviewed, full-text articles from 2016-2021. To
maintain relevancy and satisfy university requirements, I selected a minimum of 85% of
literature review sources published within 5 years of this study’s completion date. From
the search results of peer-reviewed articles, I analyzed 83 articles relevant to my area of
study and the conceptual framework for the review of the literature. Of the 83 articles, 6
(7%) were published before 2016.
Open Innovation
OI is a business strategy that Chesbrough proposed in 2003. Chesbrough (2017)
described the use of purposive inflows and outflows of knowledge to accelerate internal
innovation and reduce the cost of R&D. Zhao et al. (2016) said the process of innovation
has relied on external participants for many years and that enterprises always rely on both
inflow and outflow of ideas, resources, and individuals. Furthermore, Conrado, et al.,
(2017) asserted that sharing of resources across organizations to support OI is an old idea.
Conrado et al. posited that the scientiﬁc community is sharing more readily in recent
years. External search for information and its integration in the context of OI is one
practice that can lead to increased success in R&D (Rauter et al., 2018).
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Leaders can no longer rely only on internal resources to innovate. Zhao et al.
(2016) said with economic globalization, managers of businesses can no longer rely
solely on internal innovation to be successful. Leaders must develop resourceful methods
to develop innovative products. Consequently, many leaders are focused on
implementing OI to improve their product lines and sustain their competitive advantage.
Cammarano et al. (2019) advocated that leaders adopt OI strategies to pursue exploration
and diversiﬁcation that may lead to radical innovation.
Leaders that properly implement OI increase the innovation performance of firms.
OI consists of many different practices and is not a dichotomous phenomenon. The main
tenets of OI are collaborations with external partners, exploration of knowledge and
technology, and exploitation of internal resources (Uribe-Echeberria et al., 2019).
There are currently three recognized forms of OI. Managers engaged in bringing
technologies into the firm are involved in inbound OI (Barchi& Greco, 2018; Marcolin et
al., 2017; Shin et al., 2018). Inbound OI is a strategy managers' use to enhance
employees’ knowledge necessary for meaningful innovations. Conversely, managers
selling or licensing their internal innovations to other companies are engaged in outbound
OI activities (Barchi& Greco, 2018; Marcolin et al., 2017; Shin et al., 2018). Leaders
engaging in outbound OI sell unused innovations and technologies to obtain a pecuniary
benefit. Collaborating, cooperating, and joint ventures to develop innovations are referred
to as coupled OI because the innovation and exploitation process involves joint ventures
(Marcolin et al., 2017; Shin et al., 2018). Regardless of the OI practice, the objective is to
improve the firm’s competitive advantage.
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Despite the potential beneﬁts of OI, firm leaders have encountered difﬁculties of
successfully implementing OI. Cui et al. (2015) noted a survey of 107 European ﬁrms
showed that 48% of managers were concerned with the difﬁculty of incorporating
external knowledge into their innovation process. Incorporating external knowledge and
technologies into organizations is one of the central tenets of OI. Cui et al. (2015) said
signiﬁcant internal supporting resources are vital to unlocking OI’s potential to contribute
to innovation performance.
Absorptive capacity is critical for managers assimilating external knowledge and
technologies into a company (Milutinović et al., 2017). Absorptive capacity is the
leader’s ability to recognize the value of new information, then integrate the information
and apply it to marketable products (Fisher & Qualls, 2018; Greco et al., 2016; Xia &
Roper, 2016; Xie et al., 2018). Greco et al. (2019) said OI strategies may improve
innovation by shortening the innovator’s learning curve and fostering organizational
learning. Decreasing the innovators’ learning curve can lead to value capture more
swiftly.
Milutinović et al. (2017) suggested IT-based tools can facilitate access to a large
variety of ideas and accelerate the development of innovative new products and services.
The joining of the OI paradigm and IT results in platforms for managers to facilitate
easier access for customers and other potential participants willing to independently
contribute to solving the specific problems of the company.
The success of a business depends as much on the business model design and
implementation as it does on the selection of technologies and operation of tangible
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assets and equipment (Teece, 2018). Organizational leaders can use a business model as a
guide to provide a pathway by which technological innovation and knowledge combined
with the use of tangible and intangible assets are transformed into proﬁts.
OI Implementation
To implement OI, organizational capabilities may need a higher level of
development than closed innovation. Von Briel and Recker (2017) said the
implementation of OI is not a straightforward process. Von Briel and Recker argued that
even in an organization comfortable with embracing innovation a failed OI project
implementation is possible. It is important to consider several potential barriers before
engaging in OI such as the industry context, legal environment, supportive processes,
innovation maturity, commitment, and the participants (Von Briel& Recker, 2017).
Hosseini et al. (2017) said OI implementation needs a different employee mentality
in comparison to a closed innovation environment. Hosseini et al. identified six high-level
capabilities that are needed to implement OI strategies: strategic alignment, governance,
methods, IT, people, and culture. Hosseini et al. proposed OICF expounded on the inbound
OI and the coupled OI forms but Hosseini et al. proposed OICF did not address the
capabilities needed for outbound OI. Outbound OI is less common than the other two
categories of OI.
The foundational theory that OICF draws from is related to capability
development. Proponents of the resource-based view (RBV) consider capabilities and
assets as resources. With the RBV, assets can be tangible or intangible that organizational
leaders can use to create a competitive advantage (Barney,1991; Barney et al., 2011;
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Hosseini et al., 2017). Managers have resources that can help them to achieve a
competitive advantage (Barney, 1991; Barney et al., 2011; Hosseini et al., 2017).
Managers can sustain competitive advantage if their product or service has four
attributes: value, rareness, imitability, and non-substitutable (Barney, 1991; Barney et al.,
2011). An organization's employees have capabilities that are considered resources and if
developed can provide a competitive advantage.
Proponents of the dynamic capability theory (DCT) extend the RBV and
differentiate between operational and dynamic capabilities. The concept of dynamic
capabilities arises from a key limitation of the RBV of the firm. Dynamic resources help
leaders of firms adjust their employee’s capability mix to adapt and keep the firm’s
competitive advantage (Smart et al., 2007; Teece, 2018).
Firms will inevitably not be strong in all aspects. A manager of a ﬁrm might excel
at discovering new opportunities but be weak in terms of identifying new business
models to exploit them. Leaders can use an OI business model to achieve competitive
advantages providing they implement OI properly. Strategic alignment, governance,
methods, IT, people, and culture can potentially provide a framework to guide managers
in the pharmaceutical industry to implement OI successfully.
Strategic alignment.
Leaders in organizations must be able to adapt their OI processes in response to
changes in their corporate environment. Leaders of firms need to make strategic decisions
for OI to be successful. One such decision leaders need to make is how many channels
and external resources will be used for implementing OI. Furthermore, leaders should
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consider levels of engagement in terms of these different collaborations. To garner
benefits from OI, organizational leaders must align OI strategies with business strategies
and engage with external partners.
A proper degree of engagement with external partners that aligns with
corresponding internal resources and processes is essential for improving the
organization’s innovation performance with OI strategies (Dahlander et al., 2016).
Leaders implementing OI need to provide systems and resources to discover
opportunities and absorb ideas into their companies. Cui et al. (2015)said IT strategy
alignment is directly linked to the success of the OI strategy. The alignment between IT
strategies and the extent to which a leader uses OI strategies is critical for innovation
success.
IT is a vital component for leaders searching for OI projects. A proper degree of
openness that goes along with corresponding internal resources and processes is essential
for improving organizations’ innovation performance with OI strategies. Leaders of firms
implementing OI need to provide mechanisms and resources to discover innovative
opportunities and absorb them into the company.
Cui et al. (2015) analyzed data from 225 ﬁrms engaged in OI in China and
concluded that the alignment between IT ﬂexibility and breadth enhances innovation and
innovation volume, while the alignment between IT integration and depth positively
affects innovation volume only. Cui et al. suggested ﬁrms need IT to transfer both
external and internal knowledge to be competitive. Significant advances in IT have
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helped leaders to transfer knowledge into and out of companies, easing the pathway to
implementing OI.
For a ﬁrm to beneﬁt from OI, there is an initial investment in resources needed to
increase the firm’s absorptive capacity. Absorptive capacity is the ability of an
organizational leader to manage new knowledge and integrate new information into the
organization and across departments (Xia & Roper, 2016; Xie et al., 2018). Rafique et al.
(2018) argued that absorptive capacity is a function of infrastructure as well as the
employees of the organization.
Furthermore, Brunswicker and Chesbrough (2018) reported that in their most
recent survey compared to their 2014 findings, 2.5 % of respondents abandoned the OI
strategy for several reasons. Brunswicker and Chesbrough (2018) reported the
respondents that abandoned the OI strategy frequently chose a “lack of required
organizational structure,” followed by “no perceived benefits,” “too risky for assets and
IP,” “too difficult to manage,” “lack of management capabilities,” and “too expensive.
These results led to Brunswicker and Chesbrough (2018) to conclude that difficulties
organizing for OI and implementing OI, may have led to manager’s frustration resulting
in the abandonment of the OI strategy. Manager's frustration and difficulties with
organizing for OI are other reasons supporting the need for an OICF.
Leaders who can establish the availability of several external channels for
gathering knowledge may grant access to innovation capabilities that a ﬁrm does not hold
(Fu et al., 2018). The innovations that leaders discover using these external channels may
need infrastructure, technology, resources, and trained employees in the firm to
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successfully integrate these innovations into the business. Moreover, the firm’s managers
may need to decide which channels provide the largest return on investment as the
manager decides which channels to implement. R&D managers may ﬁnd existing ideas
or technologies outside their organizational boundaries and integrate the ideas and
technologies to start or enhance internal R&D activities provided they have the available
absorptive capacity.
While implementing OI strategies, managers of firms need to be aware of the Ushaped relationship (curvilinear) between adopting external technologies and a firm’s
innovation performance. Although OI may help bolster a company’s innovative
performance, if managers start too many projects at one time OI may lead to diminishing
returns (Dahlander et al., 2016). Companies need the absorptive capacity to integrate new
knowledge and technology. Greco et al. (2016) indicated several authors found that
speciﬁc OI strategies have a positive effect on economic and industrial innovation
performance. However, Greco et al. argued over-search and over-collaboration might
reduce the benefit of OIs marginal returns when a business leader engages with many
external innovation partners. Greco et al. conjectured that many external innovation
channels (search breadth) used by a leader, the extent to which the leader’s ﬁrm engages
with the external channels (search depth), and the extent to which a leader of a ﬁrm
collaborates through different external channels (coupled OI) is curvilinearly related with
innovation performance.
There is a ceiling to the level of new information that employees can master. Qi
Dong and McCarthy (2019) argued there is a maximum level of new knowledge
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assimilation that employees in a firm can process. Furthermore, the speed at which this
knowledge saturation point is reached is influenced by the quantity of information and
the degree of difference between the new information and the existing knowledge of the
employees in the firm. Once the maximum level of new knowledge is reached, more
information can lead to a reduced chance of developing breakthrough innovations (Qi
Dong & McCarthy, 2019). As leaders increase the number of external relationships
innovation performance increases up to a point and then innovation performance
diminishes with the addition of more external relationships. Too many projects started
without the absorptive capacity to manage the projects, will lead to failure.
In addition to absorptive capacity, managers should consider their firms’ industry
and business environment before engaging in OI practices. Naqshbandi (2018) indicated
that firms’ organizational characteristics are important to OI implementation. In this
regard, Naqshbandi et al. (2019) contended that leaders in the pharmaceutical industry
chose licensing, mergers, and acquisitions, and external collaborations while adopting OI.
Firm leaders use these modes of OI engagement based on their organizational
characteristics, such as size, age, market orientation, and industry type.
Naqshbandi (2018) highlighted that most of the firm’s organizational
characteristics are related to OI and these attributes determine how the firm’s managers
engage in OI. Naqshbandi (2018) research has practical implications and provides
insights to managers regarding the firm, industry, market, and ownership characteristics
that are favorable towards engagement in OI. Naqshbandi (2018) showed that leading
companies in the pharmaceutical industry such as Novartis and Roche, chose licensing,
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mergers and acquisitions, and external collaborations while adopting OI. Naqshbandi
(2018) identified how firm leaders that engage in OI in different industries differ in their
organizational values, such as internal integration and external adaptation. External
adaptation andinternal integration are the core challenges leaders of organizations need to
overcome for their organizations to remain viable. Naqshbandi (2018) findings indicated
that firm leaders’ in the computer, electronics, and pharmaceutical industries focused
more on internal integration and external adaptation, while most leaders in the aerospace
industry placed less importance on internal integration and external adaptation. Managers
of firms considering OI strategies should be careful in choosing the appropriate model of
innovation for their firm’s organizational characteristics to attain a competitive market
position.
It is important for leaders to choose the appropriate OI model to be successful.
Managers of firms need to identify their OI model based on their industry, market and
ownership characteristics (Naqshbandi, 2018). While OI may aid leaders in enjoying a
competitive market position through the elimination of traditional barriers, an
inappropriate choice of the OI model may lead a firm towards unfavorable outcomes
(Bican et al., 2017). Strategically, using OI correctly is important for an organization’s
success while implementing this business model.
Governance.
Managers implementing OI strategies must decide on a proper governance
model. Hosseini et al. (2017) suggested OI governance refers to the establishment and
operation of proper mechanisms to monitor and continuously improve innovation
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performance. Organizations use the internal processes to manage OI more efficiently and
effectively since it has been shown that OI management influences the effect of OI in
performance (Musawir et al., 2020; Uribe-Echeberria et al., 2019). Leaders of
organizations must decide when to use specific OI strategies (e.g. partnerships,
innovation contests, and communities) and closed forms of innovation (e.g. authoritybased and consensus-based hierarchy) (Hewitt-Dundas & Roper, 2018). Aligned with
Hosseini et al., Bican et al. (2017) posited that using the proper governance for OI is a
success factor. Different governance models may be better for some projects but not
others and different governance models require distinct approaches to project
management and selection.
By selecting the correct innovation implementation strategy, organizational
leaders can enhance their followers’ speed and efficacy of new knowledge assimilation
and utilization and subsequently intellectual property right choices, (e.g. patents,
copyrights, or trademarks). Bican et al. (2017) raised awareness of such innovation
management challenges within R&D processes, as well as strategic intellectual property
management by multiple parties. OI models have porous ﬁrm boundaries that result in
less proprietary control and increased coordination costs, requiring a joint evaluation of
OI and intellectual property (Foege, et al., 2019; Lauritzen & Karafyllia, 2019; Vilas,
Lopes, & de Carvalho, 2018). Researchers refer to the balance between OI
implementation and managing the intellectual property as the OI paradox.
With OI, managers depend on collaborations with innovation partners external to
the organization. The governance of these OI projects requires leaders to address
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governance-related issues, such as OI decision making, roles and responsibilities, partner
relationship management, and managing intellectual property (IP) (Hosseini et al., 2017;
Mi & Feng, 2019). The governance-related issues are also linked to managing the
absorptive capacity of the firm, a critical success factor. Clear management processes
help managers work more efficiently.
Klarner et al. (2019) multiple-case study of four pharmaceutical companies
revealed a sequential process of board members' involvement in governance. Klarner et
al. (2019) discovered directors with expertise govern scientific innovation, followed by
the full board’s involvement in its strategic aspects. Klarner et al. (2019) noted the extent
of director involvement varied across board levels in terms of the direction (proactive or
reactive), timing (regular or spontaneous), and the extent of formality of exchanges
between directors and organizational members. Scholars have argued that directors’
knowledge and expertise is a prerequisite for effective board involvement in the strategy.
Mi and Feng (2019) findings suggest the board of directors is the main decision-maker in
business activities and the larger the board membership the less efficient decisionmaking. Inefficient decision-making tends to lead to reduced innovation because of a
decline in the efficiency of communication among board members. Furthermore, Klarner
et al. contend that the director's human capital is important for governing a multifaceted
and long-term strategic issue such as innovation, which can be defined as the adoption of
new ideas, whether it be a new product, process, service, technology, or practice.
Klarner et al. (2019) research revealed that two elements constitute board
involvement in product innovation. First, scientific directors engage through
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differentiated involvement, characterized by knowledge exchanges that changed in their
direction, timing, and formality. Klarner et al. findings indicated directors shared their
human capital with several executives and employees at the lower ranks, and the lower
ranks provided information on company-specific innovation activities. Second, the full
board monitors and provides advice through controlled involvement, characterized by
unidirectional knowledge exchanges with fixed timing and formality. Klarner et al.
findings indicated directors were involved in innovation from the early research stage of
idea generation and testing to the more advanced innovation stage of implementation.
Moreover, according to some research, middle managers are vitally important to
OI processes and activities for their ability to smooth the absorptive capacity of the firm.
Rafique et al. (2018) research suggested the importance of role specificity of middle
managers to smooth absorptive capacity processes. The role specificity of middle
managers aligns with Hosseini et al. findings that official roles and responsibilities can
help managers with managing the absorptive capacity problem. Rafique et al. research
indicated that middle managers with little absorptive capacity are often pulled in many
directions diverting their attention and making them less effective. Undoubtedly, defining
the roles and responsibilities of the managers can help lessen this burden on managers by
better defining their roles and available resources.
In addition to defined roles and responsibilities, the governance of OI projects
need well-defined processes for the assignment of IP evolving from OI collaborations.
Toma et al., (2018) used a single-case study of R&D intensive firms to investigate how
the leaders of firms adopt IP strategies during OI practices. Toma et al. suggested leaders
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of R&D intensive firms tend to engage in OI processes with various research partners,
such as customers, suppliers, and employees, and therefore these firms require
Intellectual Property (IP) strategies to protect their IP. For this reason, proper IP
protection strategy should use all the available tools, such as registered and unregistered
IP rights (patents, copyrights, trademarks, non-disclosure agreements (NDA)) (Bican et
al., 2017; Biswas & Akroyd, 2016; Brunswicker & Chesbrough, 2018; Toma et al.,
2018).
Similarly, Hosseini et al. suggest that IP is very important to the OI business
model and conceded the more open a business is the more challenging it is to protect its
IP. Leaders sharing selective information with OI partners are rewarded through an
improvement in the quality of returned information (Barchi & Greco, 2018). Therefore,
organizational leaders need the ability to balance and selectively define the optimal
amount of information to disclose. Brunswicker and Chesbrough (2018) researched OI at
the project level and their findings suggest the careful design of openness, in terms of
knowledge sharing and IP control, the formalization of processes, and the role of top
management, play a significant role in managing OI at the project level.
In contrast to Brunswicker and Chesbrough (2018), Toma et al. (2018), and
Hosseini et al. (2017), Oltra et al. (2018) suggest that a lower degree of formalization and
higher decentralization makes inbound, outbound, and coupled OI more effective at
influencing positive firm performance. Oltra et al. (2018) argued that formalization is a
moderating variable that decreases the effect of OI on performance. Further, the effect of
formalized systems affects employees’ work and interactions, possibly impeding the
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integration across functions and hindering creativity, collaborative learning, and
flexibility (Oltra et al., 2018). Pharmaceutical leaders who emphasize open
communication also nurture an environment that is conducive to team member
innovation.
Biswas and Akroyd (2016) similar to Brunswicker and Chesbrough (2018), Toma
et al. (2018), and Hosseini et al. (2017), suggested the stage-gate process is a common
control mechanism used for project management and suggested that a hybrid stage-gate
open innovation process may assist managers with the co-development of new products.
The hybrid stage-gate open innovation process indicated a process that is a hybrid of a
formalized process with less decentralization. Biswas and Akroyd (2016) posited it is
important to examine the governance of interfirm co-development projects in an OI
context to determine the optimal model for governance. Biswas and Akroyd (2016)
argued the stage-gate process can enable the development of trust and cooperation which
supports the co-development relationship. Biswas and Akroyd's (2016) study findings
imply that a stage-gate process can be a flexible governance mechanism, which leaders
can adapt over time in relation to the needs of the co-development partners in an OI
setting.
Methods.
Hosseini et al., (2017) suggested to be successful with open innovation (OI)
projects, leaders need to have well-defined methods and processes for knowledge
exploration, retention, and exploitation. Additionally, methods that help to facilitate
interactions among OI partners are also important and increase the effectiveness of OI
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relationships (Olk & West, 2020). Processes that encourage social interactions may aid in
improving the probability of innovation. Leaders need to consider ways to promote social
interactions within the project teams as they develop processes to manage and enhance
OI.
Toma et al. (2018), and Biswas and Akroyd (2016) encouraged managers to
develop processes that provide some degree of control over the innovation process.
Processes that provide control over the innovation process are in contrast to Oltra et al.
(2018) assertion that formalization of processes hinders the innovation environment
because it obstructs the free flow of information. The stage-gate hybrid method suggested
by Biswas and Akroyd (2016), is possibly a logical compromise that may help manage
the process of OI without limiting the innovator's creativity.
External collaborations are of great importance to the implementation of OI
projects. Cheng et al. (2019) highlighted the importance of relationships external to the
organization and suggested collaborations between leaders of firms are positively related
to the effectiveness of the outcomes of OI projects. External collaborations are one of the
most important requirements of a firm for carrying out its OI business transactions as the
external collaborators are the ones, who support OI in varied instances (Olk & West,
2020). Cheng et. al. defined collaborators as the competitors, partners, and even the
suppliers, who are responsible for enhancing the knowledge of the firm's leaders and
employees in a variety of ways. The social interactions with these external collaborators
influence the positive impacts of OI on organizational performance.
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Furthermore, Cheng et al. (2019) studied the impact of the organizational learning
capability of a firm on the manager's implementation of OI. Cheng et al. concluded OI is
a business model, that incorporates not only the internal but also the external
organizational factors associated with the organization of the firm for the purpose of
attaining competitive advantage and sustaining the advantage in the target market. In this
context, Cheng et al. concluded that organizational learning capability plays a significant
role in maintaining a proper learning environment in the workplace to enhance the
knowledge and awareness of the management and employees regarding their work
process. Leaders who cultivate the organizational learning capability may improve the
efficiency level and maximize the performance of the company as a whole. Cheng et al.
suggested organizational learning capability is positively related to the effectiveness of
the outcomes of open innovation.
Moreover, Cheng et al. (2019) research demonstrated that knowledge is
enormously important to a firm. Cheng et. al suggested knowledge is one of the primary
resources for any organization to innovate or to gain a competitive advantage. The
majority of leading companies invest a large number of resources on the process of
knowledge sharing as the entire work process depends on the knowledge that is shared
not only within the firms but also with the external firms such as the customers (Bican et
al., 2017). The large investment in knowledge sharing between firms may result in more
successful innovation outcomes.
Cheng et al. (2019) concluded that OI includes the different aspects that an
organizational leader can use towards sustainable product development for a longer span
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of time. These factors are mostly comprised of the three elements specifically knowledge
sharing within and outside the firm, the inclusion of external collaboration/partnership,
and lastly the proper implementation of the organizational learning capability within the
operational procedures. The knowledge sharing within and outside the firm undoubtedly
support ensuring that the outcomes of OI are highly effective concerning the
organizational learning capability i.e., and creation of a learning environment within the
workplace.
Moreover, with the increase in the amount of knowledge sharing between leaders
and employees within and outside the firms, the effectiveness of OI practices rise. Cheng
et. al. suggested a second factor that focuses on external collaborations results in positive
impacts due to the inclusion of external partners such as the supplier firm’s managers and
employees. The inclusion of external collaborators increases the effectiveness of the OI
strategy.
To ensure compatibility between partnering ﬁrms, leaders should select the right
partner. Leaders should select partners with similarities in approaches, priorities, and
processes that are beneﬁcial for external relations (Bican et al., 2017). Furthermore,
partner similarity with regard to knowledge, organizational arrangements, institutional
frameworks, or physical distances, support OI, and shared learning. As a source for new
knowledge, networking supports the commercialization of internal knowledge and is
regarded as a key characteristic of OI ﬁrms. Methods of networking include the
placement of technology scouts, co-funding activities at incubators, and the creation of
collaboration internet portals (Bican et al., 2017).
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Bican et al. (2017) suggested that individuals’ tendencies to prefer collaboration
with existing partners often leads to decreased external networking capabilities.
Consequently, these leaders can miss out on new opportunities and new external
partnerships. To overcome the complexity of integrating new partners and binding
intellectual property arrangements, leaders foster networking capabilities through the
formation of transaction-light partnerships (Bican et al., 2017). The transaction-light
partnerships involve non-essential development areas and standard intellectual property
protection contracts. The transaction-light partnerships are intended to support the
building of relationships between the leaders of collaborating firms without significant
commitment. Leaders can use transaction-light partnerships to mitigate the risk of
engaging in external relationships.
Some leaders establish separate internal business groups to manage OI projects.
The establishment of separate OI business groups improves the utilization of internal and
external knowledge and resources. The efficient use of resources by a separate internal OI
business group can help leaders manage the absorptive capacity.
Managers can expand their firm’s reach and increase the probability of their
company innovating by developing external alliances. Martinez, Zouaghi, and Garcia
(2017) demonstrated expanding a firm's boundaries by engaging in external alliances can
enhance the internal R&D efforts. Martinez et al. suggested little is known about how
managers can operationally leverage the potential beneﬁts of OI to create an innovative
advantage. Hosseini et. al. proposed the OICF to potentially help managers implement
OI. However, Hosseini et. al. suggested for an organizational leader to apply the OICF,
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the leader of the organization will need to account for contextual factors. Further research
should thus focus on specific capability areas considering contextual factors e.g. industry,
size, etc.
Fisher and Qualls (2018), through the lens of the knowledge perspective of
interﬁrm OI, posited that managers of firms should source, screen, evaluate, acquire, and
leverage external knowledge resources for their innovation processes. Fisher and Qualls
(2018) assert OI necessitates an external focus and greater consideration to coordinating
the use of external knowledge. Similar to Hosseini et al. (2017) OICF, Fisher and Qualls
(2018) suggested managers may need systematic methods for capturing the knowledge
that they discover as they scan the external environment. Effectively capturing
knowledge is a capability that enables managers to be more aggressive at leveraging
external knowledge. Leaders using interﬁrm OI practices attempt to manage the
combination of internal and external knowledge to create new products.
Furthermore, Fisher and Qualls (2018) suggested that proponents of the
knowledge perspective emphasize the company's external search processes to actively
seek, identify, and gather novel ideas to improve new product design and development.
Similarly, Hosseini et al. (2017) described the need for knowledge exploration, retention,
and exploitation in the OICF. Fisher and Qualls (2018) posited knowledge search is often
conceptualized in terms of breadth, which is the number and range of different types of
external channels of information. Also, knowledge search is frequently described in terms
of depth, which is how deeply the ﬁrm utilizes the different external knowledge sources.
The breadth and depth of external knowledge search affect various innovation outcomes,
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such as the number of innovations and product innovativeness. Fisher and Qualls (2018)
suggested advocates of the knowledge perspective of interﬁrm OI recognize that the
method by which the knowledge output is shared is critical to achieving success.
Advocates of the knowledge perspective view explain how freely available external
knowledge can be internalized by ﬁrms in their efforts to develop new products, and how
the internal knowledge that is accumulated by ﬁrms can be externalized through various
channels.
Fisher and Qualls (2018) also viewed OI through the relationship-based
perspective of interﬁrm open innovation. The relationship-based perspective of interﬁrm
OI advocates cooperation with external leaders of firms similar to the OICF proposition.
Interﬁrm relationships are critical to discovering, sharing, internalizing, and leveraging
the external knowledge that is central to interﬁrm OI (Fisher & Qualls, 2018). The extent
that managers can access, and leverage knowledge depends on how they interact with
external partners. A leader of a ﬁrm’s position in an innovation network influences
effective collaborative relationships.
Accelerators and science parks. A limitation of the OICF is that it does not
address a leader's use of accelerators and science parks. These strategies are in their
nascent stage therefore, these strategies have not been thoroughly researched. The
accelerators and science parks are recent methodologies for knowledge exploration,
retention, and exploitation. Richter et al. (2018) suggested corporate accelerators are
organizational strategies intended to bring together leaders of innovative new ventures
and startups with specialist knowledge and creativity as well as the experience and
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financial resources of established companies (Richter et al. 2018). A leader’s objective
for the use of an accelerator program is to open the innovation process and actively profit
from the innovative capacity of new ventures.
Richter et al. (2018) posited that an accelerator program functions as a
performance filter, which excludes likely failures early in the innovation process. The
uncertainty, exploration, and ambiguity usually associated with innovation are reduced
through the application of strict processes, assessment criteria, and decision points within
the corporate accelerator program. A corporate accelerator program provides welldefined conditions supporting managers in keeping the creativity of startups under
control and directed in the interests of the firm. Richter et al. suggested an established
company can extract innovations from the creative and enthusiastic participants, who
often originate from a wide range of educational and industrial environments. Leaders
implementing corporate accelerator programs provide a controlled environment away
from the functional management of the firm. Richter et al. conceded there is little
empirical data to support the corporate accelerator program strategy although the concept
sounds feasible.
Science technology parks (STPs) emerged from the relationships among the
leaders of universities, industries, and governments (Robaczewska et al., 2019; Silva et
al., 2020). Encouraging the cooperation of leaders in university-industry to promote
innovation and increase innovation performance is one of the most important strategies of
developed and developing countries. The concept of the STP was developed as early as
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the 1980s. The STP concept was called the Marshallian district (Scaringella &
Radziwonb, 2018).
The Marshallian district is based on economies of scale achieved by leaders of
ﬁrms (Scaringella & Radziwonb, 2018). A high degree of industrial localization oﬀers
good opportunities to achieve economies of scale and reduce costs (e.g. STPs) (Silva et
al., 2020). Furthermore, the reduction of resistance has a positive impact on reducing
transaction costs. Leaders can use an industrial district to divide tasks, jobs, and value
chain activities among local small and medium-sized enterprises (SMEs). In a defined
setting (e.g. science park), small and medium-size ﬁrms beneﬁt from knowledge
spillovers (disclosures). The combination of colocation, limited transaction costs, and
high specialization are important elements of the Marshallian districts (Scaringella &
Radziwonb, 2018). The STP is a strategy that leaders may use to collocate near firms
with employees with many different capabilities.
Information Technology
Hosseini et al. (2017) posited that information technology is very important for
knowledge search, retention, and exploitation as viewed through the lens of the OICF.
Hosseini et. al. emphasized the need for collaborations and sharing of information to
effectively implement OI strategies. IT is a tool that can be used to facilitate the
collaboration process and information sharing (Ettlinger, 2017; Bican et al., 2017;
Milutinović et al., 2017; Matricano et al., 2019). Sharing information is needed externally
and internally for innovators to be aware of the resources available to innovate.
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Information technology (IT) capability assists leaders of ﬁrms to acquire, transform, and
leverage external knowledge.
Leaders can leverage IT to search for new knowledge. Information technology
(IT)-enabled knowledge exploration may include environmental scanning techniques
such as search platforms like the pharmaceutical company Lilly’s InnoCentive
crowdsourcing platform, or advanced data mining tools that help search web pages, the
scientific literature, and global patent databases for relevant ideas and technologies
(Carter et al., 2017; Christensen & Karlsson, 2017; Cui et al., 2015; Gkypali et al., 2017;
Ettlinger, 2017). Von Briel and Recker (2017) suggested examples of successful OI
initiatives found in the literature range from idea gathering to online user innovation
communities. Also, managers of organizational innovation networks combine participant
resources to generate ideas in the early stages of the innovation process to facilitate
successful later stages of development.
Crowdsourcing is another IT tool that leaders can use to elicit ideas for a variety
of stages in the innovation process (Ettlinger, 2017; Jespersen, 2018; Stroh, 2019). The
internet has helped to decentralize the drug discovery process which has become a more
bottom-up process. Crowdsourcing is one tool that has made it possible to search for
ideas at a lower cost (Carter et al., 2017; Ettlinger, 2017; Jespersen, 2018; Stroh, 2019).
Carter et al., suggested pharmaceutical company leaders typically establish their Internet
portals to solicit solutions from community participants. GlaxoSmithKline (GSK) and
Bayer are examples of pharmaceutical companies that have an Internet portal for
crowdsourcing to solicit ideas from the community. Other pharmaceutical companies’
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leaders may use specialist brokers who have crowdsourcing platforms such as
NineSigma, or Kaggle (Gillespie et al., 2019). Participants from crowdsourcing platforms
have been credited with providing relevant input into ten drug discovery projects at Bayer
e.g. Grants4Targets (Carter et al., 2017). Carter et al., suggested Boehringer Ingelheim
leaders’ have pursued several crowdsourcing projects with InnoCentive that ranged from
studying new translational models of psychiatric disease to new approaches for the in
vivo modulation of gene expression in lymphocytes.
Notwithstanding this scientific progress, some researchers still argue that OI may
not be an effective innovation strategy. Von Briel and Recker (2017) argued that OI in its
many forms is not necessarily an effective strategy. Practices that have been identified in
successful implementations of OI do not necessarily prevent failures. Leaders' OI failures
are supported by ample research and so the need for an effective implementation
framework (Ettlinger, 2017). Indeed, these idea-generating platforms suffer from one
major drawback, innovation requires that a creative idea be reduced to practice in the
form of an actionable plan (Matricano et al., 2019). The process of converting an idea
into action is an iterative process that needs to be collaborative and free from restrictions
(Stroh, 2019). Von Briel and Recker (2017) provide executives in organizations seeking
to establish online OI communities with a set of managerial lessons learned and a
framework with checkpoints and guidelines. Von Briel and Recker (2017) posited several
potential barriers to consider before beginning an online community: (a) Industry context,
(b) Legal environment, (c) Supportive processes, (d) Innovation mindset, (e)
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Commitment, and (f) Participant community. All these barriers are critical to evaluate
before initiating an online OI community.
Von Briel and Recker (2017) demonstrated how the successful implementation of
an online OI community depends on several interrelated conditions and that these
implementations often face unique challenges associated with the context of the business.
While the generalization of the Von Briel and Recker (2017) findings is limited because
of the single case study design, their approach provides an unusual opportunity to learn
from failure. Von Briel and Recker (2017) posited there is little known about OI failures
or the reasons for OI failures. Some prominent examples of OI failures include Boeing,
LEGO, and some pharmaceutical implementations. Perhaps studying the causes of these
failures could help business leaders avoid these implementation pitfalls.
The underlying reasons for the innovation failures in these leaders’ companies
were related to strategy, communication, and a lack of knowledge of the complexity and
intricacies of using open innovation strategies. The LEGO managers' primary mistake
which led them to failure was producing products the customers did not want. LEGO
management had lost sight of the needs of their customers. Organizations have
traditionally relied solely on internal knowledge to drive innovation (closed innovation).
However, such closed innovation limits the flow of ideas and can perpetuate negative
groupthink. When the LEGO leaders realized a need to reconnect with their customers
the LEGO managers launched a program to engage users in the development of products
(Andersen & Gadde, 2019).
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The LEGO managers used an open innovation strategy that encouraged
customers to interact, share, and vote for ideas regarding the kinds of products or services
they would like to see LEGO develop (Cina & Cummings, 2018). The crowdsourcing
platform the LEGO managers implemented was called ‘Cuusoo’ (Japanese for ‘wish’)
(Cina & Cummings, 2018). The LEGO managers, opening lines of communication with
customers in this way, improved engagement with their growing customer base and their
future product developments came to be informed by the user community. This open
innovation strategy brought the company into greater sync with industry trends and
customer needs. The LEGO company has come to be recognized as a world leader in toy
innovation with high levels of growth and posting a record profit of $1.87 billion in 2016
(Cina & Cummings, 2018).
Boeing experience another example of the difficulty in implementing OI. Boeing
managers needed a better adaptation of organizational and development practices to the
innovation introduced by their decisions (Shenhar et al., 2016). The Boeing management
team experienced difficulties developing its highly innovative Dreamliner aircraft. The
Boeings Dreamliner engineers’ first major challenge involved designing the aircraft’s
body using light-weight composite materials. The Dreamliner aircraft was to
accommodate 250 passengers on long-haul transportation for about a 20% lower fuel cost
(Shenhar et al., 2016). This change in the material was necessary for fuel savings.
Although composite materials were not new, the composite materials were never
used in such a large aircraft (Shenhar et al., 2016). The Dreamliner engineers required
more sections to assemble the fuselage than previously used for an aluminum-based
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fuselage (Shenhar et al., 2016; Tidd & Bessant, 2018). The engineers' lack of experience
with the composite materials resulted in having to redesign the plane, which significantly
delayed the Dreamliner project.
Boeing managers’ confidence in its experience and record of success led project
leaders to believe that the new project would be as successful as others. The engineers
probably underestimated the challenges and scope of innovation (Shenhar et al., 2016;
Tidd & Bessant, 2018). The managers' difficulties were a result of the following major
challenges: (a) the use of newly developed technologies, (b) outsourcing a large extent of
design to numerous, less experienced subcontractors, (c) a new business model of
revenue sharing, and (e) a new assembly model (Shenhar et al., 2016). Using these
strategies, Boeing managers helped retain competitive positioning by taking advantage of
modern technologies, and practices, but Boeing managers’ execution was less than
optimal.
Procter & Gamble (P&G) provided another example of an OI failure. The
managers made a strategic mistake in trying to implement OI. P&G managers did not
understand the complexity and intricacies of using open innovation strategies. P & G was
an early adopter of the OI strategy so there was not as much research available to guide
the managers. The P & G case study provided some of the learnings for implementing OI.
The P & G managers decentralized the firm’s research and development (R&D) to
shift P&G’s R&D to an OI model (Han et al., 2019).The P&G managers’ OI model
shifted the burden of innovation from a centralized department to business units
categorized by product type. Although shifting the innovation to business units provided
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innovators with focus and increased success rates for new product introductions, these
products did not address the unmet needs of the customers. The focus of the managers
was on the invention of new technology and not addressing the unmet needs with
innovation (Han et al., 2019). In P & G’s case, there were flaws in both the strategy and
the implementation, which ultimately led to failure.
The open innovation strategy led to organizational decentralization and reduced
collaboration between separate product groups within P & G (Han et al., 2019). This
change failed to utilize one of P&G’s competitive advantages, its conglomerate structure.
For instance, the innovators of Crest Whitestrips used bleaching technology from the
laundry business, glue technology from the paper products business, and film technology
from the food wrap department (Han et al., 2019). P & G’s centralized R&D allowed
these departments to work together to inspire innovation.
Furthermore, the compensation structure of the business unit managers also
contributed to the failure of the R&D reorganization because the managers were being
rewarded for business unit profitability (Han et al., 2019). Since R&D expenditure
lowered profits over the period, investment was not initiated unless it led to an immediate
profit, offsetting revenue growth, and rewarding managers for incremental improvements
in the products. This led to the transition from high-risk, high reward products to
incremental improvements of existing products. Shorter development periods and quicker
return on investment became the priority.
P & G re-established distinct R&D departments that pooled knowledge from
scientists, engineers, and product developers across all P&G’s product lines (Han et al.,
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2019). Furthermore, the managers started looking outside the firm for needed capabilities.
Scientists, engineers, and product developers across all P&G’s product lines were given
specific long-term targets and budgets with a significant portion of compensation derived
from qualitative metrics. This new system emphasized long-term decision making
through focused planning and was flexible enough to reward employees for visionary
innovations (Han et al., 2019). A similar compensation structure was implemented at
Johnson & Johnson with great success.
In contrast to Von Briel and Recker (2017) findings, Gillespie et al., (2019)
suggested that some sectors have embraced the paradigm shift to open innovation.
Gillespie et al., (2019) noted there is an increased uptake of OI practices by leaders of the
biopharmaceutical sector. Leaders in biopharmaceutical firms have embraced OI models
to optimize drug development. Gillespie et al., (2019) suggested the leaders of the
traditional proprietary, non-collaborative biotechnology, and pharmaceutical companies
are increasingly using principles, processes, and structures of OI to increase drug R&D
effectiveness and efficiency. Gillespie et al., (2019) distinguishes three essential elements
in the successful creation of OI partnerships: (i) culture, (ii) collaborative management
skills, and (iii) strategic capability alignment. Gillespie et al., (2019) three essential
elements are three of the six high-level factors that Hoesseini et al., (2017) identified in
the OICF proposal.
Gillespie et al., (2019) provided guidance for business leaders and scholars
interested in the managerial and strategic dimensions of applying OI to the drug
development environment. In addition, business leaders and scholars may find that using
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all six factors of the OICF may lead to more effective implementations. Leaders' use of
OI has the potential to improve quality, increase speed, and lower costs, and thus yielding
positive benefits for global health.
People
Hosseini et al. (2017) said employees and corporate OI teams play an essential
role in OI. Important capabilities that can foster innovation performance are technology
mastery, personal peer leadership, and capabilities to link to external organizations
(boundary-spanning). The latter capabilities do not need to be held by all individuals.
However, leaders need to ensure there is a sufficient number of individuals placed in the
correct functions or dedicated teams that have these capabilities. Martinez et al. (2017)
posited that knowledge, skills, and abilities used by individuals in an organization,
determine a ﬁrm's potential gains from collaborating with external organizations. Many
researchers’ findings have highlighted the importance of the employee’s knowledge,
skills, and abilities for the successful implementation of OI.
Consistent with Hosseini et al. (2017) and Martinez et al. (2017), Kratzer et al.
(2017) suggested there is an agreement that the people are central to a company’s
innovation process and drive the innovation process. Kratzer et al. posited employees in
companies perform innovation in an environment with rules and regulations that might
support or hinder innovation. The OI paradigm expects leaders of companies to engage in
external relationships for innovation. Leaders often neglect to cultivate a culture of
employee communication openness.
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Creating an internal culture of openness is important for leaders considering OI
strategies and before collaborating with external partners. Kratzer et al. (2017) argued
that establishing internal openness (unhindered communication) is important before
collaborating with external partners. The key challenges in building and developing an
innovation culture are the changes in the organization's approach and mobilizing teams to
bring products and services to the market quickly. The leader's fundamental challenge
with this process is that companies need to incorporate a view on innovation shared not
only by the company leaders but also by employees (Hannena et al., 2019).
Incorporating a view of innovation shared by the company leaders and employees may
require a significant culture change driven from the top down.
Leader and employee behavior and attitudes are important elements in shaping a
corporation's work culture and innovation culture. Kratzer et al. (2017) argued employee
behavior and attitudes are linked with cultural thinking. Employees' behavior and
attitudes are important elements in shaping a corporation's work culture and innovation
culture (Hannena, et al., 2019). Employee behavior and attitudes may facilitate the OI
process. Leaders considering using OI to enhance their internal innovation process need
to put several OI supporting processes in place to facilitate the implementation. Some of
the areas that leaders need to focus on to be successful include strategy alignment,
governance, OI methodology, employees, corporate OI teams as well as the firm’s culture
(Hosseini et al., 2017; Kratzer et al., 2017). To be successful, leaders of a firm need to
take a holistic approach when implementing OI to ensure their overall strategy is in
alignment with their business strategy, information technology, and culture.
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Culture
Hosseini et al. (2017) suggested a different mindset is imperative for OI.
Employees currently working in a closed innovation practice will need to change their
practices concerning managing ideas, knowledge, and technologies. Leaders’ and
employees’ cultural values and beliefs are critical for OI as are formal practices, which is
why leaders of organizations must implement an innovation culture that enables and
promotes OI activities (Mahdad et al., 2020). Hosseini et al. said related competencies are
OI attitude and behavior, risk attitude toward OI, and attitude toward IP management.
Not-invented-here syndrome. One challenge for leaders implementing OI is
shifting employee mindset from a closed to open innovation. As organizational leaders
shift strategies, the leaders need to consider ways to overcome the not-invented-here
(NIH) syndrome (Hannena, et al., 2019). NIH syndrome is an employee’s negative
attitude toward external knowledge exploration. Leaders need to develop strategies to
change the employees’ attitudes to be accepting of the external knowledge exploration
strategy (Hannena, et al., 2019). The failure of leaders to mitigate the NIH syndrome may
lead to a biased and incorrect evaluation of external ideas and technologies. Biased and
faulty evaluation of external ideas and technologies by managers could result in the
ineffective implementation of OI.
Not-connected-here attitude. Related to NIH, another barrier that leaders need to
overcome is the not-connected-here attitude, which reflects a negative employee attitude
toward external knowledge retention, e.g., attributable to a lack of trust in innovation
partners (Hannena, et al., 2019; Hosseini et al., 2017; Kratzer, et al., 2017). Employees'
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lack of trust in external partners can have a negative impact on information exchange
with the external partner. Both the NIH syndrome and the not-connected-here attitude
hinders the exchange of information with innovation partners (Hosseini et al., 2017).
Risk-taking tolerance. Employees suspicious of the leaders’ intentions for
external sourcing may consider external sourcing as a greater risk given a higher level of
perceived uncertainty compared with internal sourcing. Leaders being too risk-averse and
attempting to minimize risk by implementing too many risk filters may slow down the
innovation progress, potentially leading to missed opportunities and potentially leading to
failed collaborations. Leaders implementing OI need to encourage an entrepreneurial
culture tolerant of risk-taking to benefit from OI.
Leadership commitment. The level of leadership commitment and attention
impacts the effectiveness of the OI strategy. Leaders must create a work climate
conducive to OI. The articulation of goals and top-down encouragement involves written
and spoken communication (Musawir et al., 2020). Leaders’ OI success stories can be
used to inspire employees to actively search outside of an organization for new ideas and
technologies. By implementing the proper incentives, leaders can foster employees’
engagement throughout different OI activities. Leaders should consider incentives that
foster acquiring innovation from external sources. Providing incentives to employees for
acquiring innovation from external sources can support an employee's mindset in
abandoning an NIH attitude.
Governance-related culture change. The culture change must entail not only
governance-related changes but also cultural changes regarding IP management. A firm’s
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legal and IP leaders must be encouraged to adopt a positive attitude supportive of OI.
Instead of taking an excessive protective position, legal and IP leaders should encourage
employees to seek mutually beneficial agreements (Moellers et al., 2020). Sharing
knowledge with innovation partners or communities can be beneficial as the quality of
returning information improves with the amount of initially revealed information (De
Silva & Rossib, 2018). If managers convey an overprotective attitude to employees, this
may lead employees to avoid external engagement given the perceived personal and
professional risks of the unplanned disclosure of information.
Hosseini et al. posited that culture affects innovation success but concluded that
no specific OI culture exists. Nestlea et al. (2019) suggested extant research has found
superior innovation performance of ﬁrms located in research clusters. It was unclear if the
superior innovation performance was a result of the proximity of the firms, or other
unknown factors (Nestlea et al., 2019). Nestlea et al. concluded that more research was
needed to determine if the diﬀerences in the open innovation culture was the result of
membership in a cluster. Similarly, Hosseini et al. concluded more research is needed
regarding OI-enabling culture.
The high-impact organizational changes related to OI involve the adoption of
cultural changes and new approaches to the entire company governance and innovation
processes. The spread of an open innovation culture within organizational boundaries
appears as the main factor guaranteeing the sustainability of OI as a long-term strategy.
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Pharmaceutical Industry and OI Implementation
Pharmaceutical company leaders have been experiencing challenges to bring
novel therapeutic agents through the R&D process to generate a sufficient return on
investment (DiMasi, et al., 2016). The cost estimate to bring a new drug to the market
averages $2.9 billion and 13 years (DiMasi et al., 2016). Leaders in the pharmaceutical
industry have trouble discovering and developing novel therapeutics. Chesbrough and
Chen (2015) suggested pharmaceutical drug development costs have risen over the past
20 years but the number of new molecular entities (NMEs) approved has not increased.
As pharmaceutical companies reduce their R&D spending significantly to balance
their budgets, unmet medical needs will remain unaddressed (Chesbrough & Chen, 2015;
Gillespie et al., 2019; Gkypali et al., 2017; Masuccia et al., 2020; Reichman & Simpson,
2016). Much of the rising costs in drug development can be traced to work on failed
projects that are abandoned before getting to market (Chesbrough & Chen, 2015;
Reichman & Simpson, 2016). Improving the efficiency of R&D may allay the costs and
potentially lead to more therapeutics for a variety of conditions. Hosseini et al. reported
there is evidence that OI strategies can increase the net present value of projects by 70%
compared to closed innovation projects. Leaders using OI strategies are associated with
superior firm performance and higher innovative activity in both large and small-tomedium-sized companies (Battistella et al., 2017).
OI is a broad term for diverse strategies that managers use to seek external input
and public engagement and has become an essential tool with researchers, who are
increasingly turning to research collaborations, crowdsourcing, data sharing, and open-
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sourcing to address some of the most pressing problems in medicine. Notable examples
of such open drug development include initiatives formed around malaria and tropical
disease (Weng et al., 2018). Currently, there is no established OI framework for the
pharmaceutical industry that pharmaceutical leaders can use as a guide for the
implementation of OI projects.
Searching for strategies to improve the drug discovery process, leaders in the
biomedical research field are beginning to embrace OI. Shaw (2017) noted traditional
drug development models are perceived as inefficient, with the cost of research and
development continuing to rise even as production of new drugs stays constant. Shaw
(2017) noted the changes in leaders’ strategies are starting to reshape the industry. OI
practices have found their way into the drug discovery process, from target identification
and compound screening to clinical trials. Shaw (2017) argued the OI perspective poses
some risks-which include the management of collaboration and the protection of
proprietary data but in many cases, OI strategies are a more efficient and ethical way to
conduct biomedical research. In the pharmaceutical industry, practical limitations,
cultural norms, and intellectual property (IP) concerns have resulted in a development
process traditionally conducted in a carefully protected proprietary environment often
referred to as closed innovation.
Consistent with Shaw (2017), Banerjee and Siebert (2017) studied the effect of
pharmaceutical and biotech R&D leaders’ collaborative business relationships on the
firms’ research activities and drugs offered on the market. Banerjee and Siebert (2017)
indicated that large firm managers’ collaborating in the late research stage re-optimize
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their R&D pipelines and eliminate similarly aligned research projects. Managers
streamlining R&D can reduce costs and eliminate drug candidates that could potentially
limit the profits of each product. Late-stage R&D collaborations formed among leaders of
larger firms increase a firm’s research activities but reduce the number of drugs launched
in the product market. Leaders reduced the number of drugs launched in the product
market by eliminating overlapping drug products. Some researchers have highlighted that
R&D collaborations between leaders of companies have helped overcome innovation
obstacles and resulted in an increase in R&D activities. Banerjee and Siebert (2017)
studied leaders' strategies who were engaged in R&D collaborations throughout the
different stages of the drug development process from early to late stages.
Engaging in R&D collaborations at all stages of the R&D process can help
leaders manage the increasing cost of R&D. Banerjee and Siebert (2017) studied firms
where leaders engage in R&D collaborations to manage the increasing costs of drug
development. Banerjee and Siebert's (2017) findings revealed that early and late-stage
R&D collaborations have differential impacts on the technology and product markets.
More specifically, early-stage collaborations allow firms to increase R&D activities that
may eventually be transmitted to the product market and lead to an increase in the
number of drugs offered on the market.
In contrast, when leaders engage in late-stage R&D collaborations among larger
companies, leaders have less of an impact on a firm's R&D activity. Late-stage products
are less likely to need an intense R&D effort than early-stage products. Research
collaborations have been analyzed frequently in the literature and are considered to have
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socially and ethically beneficial impacts such as avoiding wasteful duplications in
research. In the pharmaceutical industry, findings from several research studies indicated
leaders engaging in R&D collaborations increase the probability of developing new
drugs. R&D collaborations allow the leaders to exploit the synergy effects and share the
costs of R&D.
Developing and exploiting innovation activities in collaboration with external
parties requires new decisions that should be delineated in when, how, with whom, with
what purpose and in what way (Battistella et al., 2017; Carter et al., 2017; Namkuk et al.,
2015). West and Bogers (2017) said inbound OI practices are more commonly used than
outbound practices in the pharmaceutical industry. Few researchers have studied the
outbound OI practices in the pharmaceutical industry. Yet, even with the extensive OI
research that has been performed, there are still many areas that remain unexplored and
warrant more research such as the use of outbound OI.
Open Innovation Capability Framework
This research project is intended to identify a potential OI implementation
framework for OI projects that pharmaceutical managers can use to engage in OI
projects. The research on OI implementation is sparse and fragmented. Few researchers
have attempted to identify the factors that may support the successful implementation of
OI. OICF comprises the outside-in and coupled OI processes and provides a
comprehensive overview of related capabilities compared to many of the other studies.
The holistic approach of the OICF can assist decision-makers in prioritizing, selecting,
and customizing the proposed capability areas for their context. Hosseini et al.
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(2017)posited that leaders of organizations should carefully analyze the relevance of the
OICF distinct capability areas in their context (e.g. industry, environment, and size).
OICF
While compiling the OICF, Hosseini et al. focused on keeping the included
capability areas as OI-specific as possible. Henceforth, the OICF captures specific
capability areas, but not necessarily unique to OI (Hosseini et al., 2017). The OICF
framework provides practitioners with a framework to further explore open innovation.
Hosseini et al. posited that most research on OI frameworks focuses on single facets of
OI. The OICF framework introduced by Hosseini et al. only covers two modes of OI, the
outside-in and coupled processes of OI. The OICF framework takes several of the
proposed theories and merges them for a more comprehensive implementation
framework.
Hosseini et al. (2017) collected the data through a literature review of OI theories
and integrated them into a larger OICF theory that takes pieces from all the theories used
to explore OI. Subsequently, Hosseini et al. validated the assumptions with a 7-point
Likert scale survey using academia and industry OI experts. One shortcoming of the
proposed OICF is that Hosseini et al. did not address the inside-out model of OI where
leaders sell unused technology or abandoned compounds for financial gain.
Inside-out model
The inside-out model may be an effective OI mode for the pharmaceutical
industry and is only beginning to be researched (Chesbrough & Chen, 2015). Toma et al.
(2018) suggested the biopharmaceutical sector could benefit from adopting OI strategies
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but conceded that pharmaceutical leaders engaging in OI may have to differentiate their
IP protection tools depending on the R&D phase. The development of therapeutic agents
goes through several stages before being a marketed product.
Additional OI framework
Battistella et al. (2017) explored the different practices, actors, and tools adopted
for opening the innovation process by small and medium-sized companies facing
difficulties in OI implementation. Battistella et al. discovered 23 practices, 20 actors, and
11 tools used in the OI processes of small and medium-sized companies. Battistella et al.
methodology used to develop the framework are consistent with the methodology
Hosseini et al. used to develop the OICF. Both researchers searched the literature and
identified the different OI practices and tools used to develop the proposed frameworks to
implement OI.
Few researchers have studied the implementation of OI projects. Battistella, et al.
(2017) suggested previous research of OI studied management challenges for effective OI
implementation, yet there was still little research on putting OI into practice and therefore
a need to study OI implementation. Battistella et al. reported that other researchers
introduced frameworks that support managers in identifying the OI practices that best fit
a specific innovation project. Battistella et al. studied different combinations of variables
related to OI practices e.g. access mode and variables related to a company’s innovation
context in terms of knowledge channels. Battistella et al. concluded, similar to Hosseini
et al. (2017) that leaders of companies need to adopt new approaches to access external
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knowledge and create competitive businesses. Identifying and engaging in external
relationships to acquire new capabilities are important to the implementation of OI.
Most empirical investigations about OI have been case studies of successful early
adopters of open innovation, and their analyses have mostly been at the company level.
Inbound OI involves a wider variety of actors and tools than outbound OI practices
(Battistella et al, 2017). OI practices such as crowdsourcing, external networking, and
scouting from external sources involve the use of external sources of knowledge through
the application of two to three different tools (Battistella et al., 2017). Consistent with
Hosseini et al. (2017) proposed OICF, the tools used for targeting, sourcing, and
acquiring valuable knowledge involved the use of IT.
Project level antecedents
Namkuk et al. (2015) suggested that future research needs to look at the project
level implementation of open innovation (OI). The project level is where the innovation
begins in R&D (Battistella et al., 2017). Namkuk et al. explored systematic relationships
between various antecedent factors and the degree of openness. Project-level openness
could be affected by team and task characteristics, such as team size, learning distance,
strategic importance, technology, and market uncertainty, and relevance to the main
business. Namkuk et al. collected data from 303 companies in Korea to identify the
antecedents that affect inbound and outbound openness. The Namkuk et al. findings
suggested six factors at the project level that could be expected to affect OI behaviors.
Subsequently, Namkuk et al. (2015) conducted an exploratory field study to learn
more about the factors six factors identified. The exploratory interviews revealed that

51
teams that already possessed sufficient capabilities to succeed on their own did not
engage in OI. Project leaders of teams should consider their teams' knowledge and
capability gap (learning distance) as an antecedent of open innovation.
Furthermore, Namkuk et al. (2015) suggested one of the most critical resources
for an R&D project is human resources, and so team size is used as a measure of the
number of employees available to a team. Accordingly, the amount of resources available
to a team is expected to affect its OI activities. Advocates of the social capital perspective
inferred that opportunities to form relationships with external parties grow as team size
grows; therefore, larger teams are more likely to benefit from more sources of external
resources than smaller teams.
Five design principles
Five design principles posited by Ollila and Ystrom (2016) were (a) presence of
participants equals influence, (b) diversity is the source of creativity, (c) multiple
identities of participants created an extended view, (d) a higher purpose unites the
participants, and (e) the participants are creators of the collaboration. Ollila and Ystrom
(2016) noted practitioners should discuss the expectations and preconceptions when
engaging in collaborative activities and the practitioners benefit by using the design
principles to facilitate the communications. The themes emphasized by Ollila and
Ystrom, (2016) are closely related to the six factors postulated by Hosseini et al. (2017).
Limited scope framework
Ya Juan Wu et al. (2016) performed a single case study using an ethnographic
approach to become closely engaged in a project for developing drugs for diabetes.
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Identifying potentially suitable drug candidates to fit the product portfolio is a very small
but important aspect of inbound OI. Ya Juan Wu et al. used a grounded approach like
Ollila and Ystrom (2016) to let the themes discovered by the researchers inform their
theory. Although Ya Juan Wu et al., research was very limited in scope their findings
discovered principles closely related to some of Hosseini et al. (2017) open innovation
capability framework (OICF).
Conclusion
The OI paradigm has received an extensive number of contributions from
different researchers that studied a variety of OI dimensions such as strategy, leadership,
and organizational structure. Inbound OI practices seem to be more prevalent than
outbound practices and not a lot of research has been performed on outbound OI
practices. Furthermore, researchers suggested that more research is needed at the project
level in different contexts. Also, OI researchers suggest organizational leaders need a
more comprehensive OI implementation framework. Currently, the approach to OI
implementation is fragmented because little research has been dedicated to this topic.
The OI approach to innovation has become very important for innovation and
technology and therefore captured the attention of managers and other leaders. These OI
practices of organizing research, development, and innovation activities could be an
eﬀective way of sharing knowledge, obtaining complementary assets, and generating new
technologies in most sectors where technological advances are rapid such as the
pharmaceutical industry.
Transition
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In Section 1, I provided the foundation for this study and discussed the basis of
the problem and the purpose of the study. The conceptual framework provided a path to
understand how pharmaceutical leaders implement OI drug development projects, and the
significance of the study supports the purpose statement. Also, in Section 1, I introduced
the research question for the study. In the review of the literature, I analyzed and
synthesized various sources of literature to achieve an in-depth analysis as it relates to the
research topic.
In Section 2, I explain the role of the researcher, participants, chosen research
method and research design, sampling method, ethical research, data collection
instrument, techniques for data collection, data organization techniques, and data
analysis. At the end of Section 2, I detail aspect of reliability and validity as it applies to
qualitative research and describe the rigor of my qualitative research.
Section 3 comprised research findings, how the findings apply to professional
practice, implications for social change, the recommendations for action. I conclude
Section 3 with my recommendations for future research, a discussion of the foundation of
the study, implementation of OI drug development projects, and my research conclusions.
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Section 2: The Project
In Section 2, I discuss my role as a researcher and describe my study participants.
This is followed by a description of the qualitative research method and single case study
research design. I describe the population and sampling followed by a discussion of
ethical research. Section 2 also includes discussion of data collection instruments, data
collection techniques, data organization techniques, and data analysis. I conclude Section
2 by explaining my strategies for improving the rigor of my research.
Purpose Statement
The purpose of this qualitative single case study was to explore strategies US
pharmaceutical company leaders used for developing and implementing OI R&D
projects. The targeted population was five US pharmaceutical R&D directors in one
pharmaceutical firm who have successfully used OI strategies to develop and implement
R&D drug development projects. The firm was headquartered in the northeastern region
of the US. My research findings may enhance US pharmaceutical leaders’ capacity to
increase ROI, decrease operational costs, and positively influence local communities
through increased tax revenues. Furthermore, efficient discovery and production of novel
therapies may lead to a better quality of life for many patients.
Role of the Researcher
The role of the researcher is central to the data collection process. The researcher
needs to be aware of how their role in research is significant. In this qualitative research, I
was the data collection instrument and played a vital role in understanding the practices
and behaviors of participants. My role was to listen to each participant’s responses and
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refrain from being judgmental while remaining focused and attentive. Furthermore, my
responsibility was to conduct ethical research following the Belmont Report. The
Belmont Report provides researchers with a set of ethical standards and guidelines they
must adhere to for the protection of participants. My role was to interview five
participants from one company, collect and analyze data, and manage interviews while
protecting the privacy of participants. I used semistructured interviews with 10 openended questions that addressed significant areas of the OICF. I used an interview protocol
to help maintain consistency in data collection between participants.
Transparency in terms of the researcher’s position, potential biases, and
assumptions is vital in terms of judging accounts of qualitative research and the
authenticity of ﬁndings. I have no direct professional relationship with participants
involved in the study; however, I work for the same employer. Participants are
geographically located in the northeast of the US. Also, participants work in a different
department at a higher pay grade than myself.
I worked in biomedical R&D for over 36 years and played an integral role in
managing in vivo research and research facilities within public and private organizations
in New York. Because of my years in biomedical research, I needed to be aware of
potential biases. Confirmation bias occurs when the researcher filters participants’
information and uses a subset of the information according to the researcher’s preexisting
beliefs (Gatlin et al., 2017; Reid et al., 2018). Confirmation bias makes people more
willing to select information that confirms a prior belief or opinion. Researchers
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practicing reflexivity while interviewing can avoid these biases (Pessoa et al., 2019). I
mitigated confirmation bias via reflexivity and questioning of my conclusions.
Participants
I used purposive nonprobability sampling to select participants for this research
study. Nonprobability sampling is appropriate for qualitative research. The purposive
sample consisted of participants who possessed the knowledge to contribute relevant
information regarding strategies for developing and implementing OI R&D projects.
Researchers using nonprobability sampling rely on their judgment when choosing
members of the population to participate in their study. Some types of research design
require researchers to decide which individual participants would be most likely to
contribute appropriate data, relevance, and depth.
The research participants selected possessed the experience and ability to
contribute relevant information regarding developing and implementing OI R&D projects
and agreed to be audiotaped. To gain access to participants, I requested organizational
cooperation to assist in identifying relevant participants. I sent a letter of organizational
cooperation (see Appendix A) to the company’s human resources and legal departments
to get permission to do research. After I received pharmaceutical organization and
Walden University Institutional Review Board (IRB) approval, I sent a recruitment letter
(see Appendix B) via email to participants to request their participation. Participants who
agreed to be interviewed were sent consent forms (see Appendix C) with the IRB
approval number (# 09-14-20-0674379) via email.
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Before interviewing participants, I received affirmative consent forms from their
email addresses. I needed to select a minimum of four participants. Gaya and Smith
(2016) said three participants are enough for a single qualitative case study design.
Creating a systematic and transparent way of obtaining participants is beneficial to
providing adequate information for a qualitative single case study (Benoot et al., 2016).
After data saturation was achieved, I determined the number of participants needed for
the study was five participants. Sim et al. (2018) said determining a qualitative sample
size a priori is problematic. Qualitative case studies do not have a set number of
participants in terms of sample size, but when data saturation is reached, more
information will no longer bring value to the study (Boddy, 2016). The initial set number
I determined for this study was four participants, but after collecting data, data saturation
was achieved with five participants.
Transcripts and audio recordings will be stored for 5 years so that only I have
access to the data. Consent to participate in the study was obtained from each participant
before conducting each interview. Sending consent forms in advance for participants to
review expedited the process of using the data for this doctoral study. Raw data is
important to save from interviews. Data will be stored on a flash drive, my computer, and
on cloud management software (OneDrive). All stored data will be password-protected
and retained for a minimum of 5 years after the study’s completion.
Research Method and Design
The research method used for this study was qualitative, and the research
design was a single case study. I chose this research method and design based on the
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nature of the topic, which involved strategies US pharmaceutical company leaders used
for developing and implementing successful OI pharmaceutical R&D projects. The
qualitative research method and the single case study design were appropriate for this
study because they can increase researchers’ understanding of a contemporary
phenomenon with the use of multiple data sources from a single organization and not
multiple organizations (Yazan, 2015; Yin, 2018).
Research Method
When conducting a research study, three research methods are available for
researchers to use qualitative, quantitative, and mixed methods. The choice of the
research method is related to the research problem and purpose (Bloomberg & Volpe,
2019). Qualitative research involves the use of multiple data sources to discover patterns
or themes under given circumstances (Kegler, et al., 2019; Merriam &Tisdell, 2016).
Qualitative data sources include interviews, observations, and company documents.
Quantitative research involves the use of instruments to accumulate data for statistical
analysis to test a theory or hypothesis (Bryant et al., 2018). The quantitative research
method was not appropriate for this study because it requires the examination of multiple
numerical variables, which was not the emphasis of this study. Mixed-methods research
combines both qualitative and quantitative methods (Bloomberg & Volpe, 2019).
Because the mixed methods approach uses the quantitative method, it did not provide the
information needed for this study, thus making it unsuitable for this research. A
qualitative research method was the most appropriate method for this study because the
qualitative methodologist relies on data sources in everyday occurrences. According to
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Kegler et al. (2019), the qualitative research method helps us understand the context,
explore new phenomena, identify new research questions, and helps to construct a
complete description of the themes or patterns relevant to the phenomenon.
Research Design
A single case study research design was the research design used for
this study. A single case study research design aligns with the qualitative process that
deals with exploring a phenomenon thoroughly in real circumstances to establish
connections that are not easily seen but are important to understanding the phenomenon
(Ganz & Ayres, 2018). The tools I used for data collection were interviews and publicly
reported company documents. A single case study research design incorporates real
situations to collect data from a variety of sources, which highlights a conclusion or set of
conclusions (Merriam &Tisdell, 2016; Yin, 2018). The single case study was most
appropriate for this study because I was exploring one organization by interviewing five
R&D directors to gain knowledge on strategies US pharmaceutical company leaders used
for developing and implementing successful OI pharmaceutical R&D projects. My
comprehensive analysis of the specific business problem provides strategies for
developing and implementing successful OI pharmaceutical R&D projects.
Researchers may also use other qualitative research designs for a study, including
ethnography, narrative inquiry, and phenomenology. Ethnographers focus on studying
human society and culture (Merriam & Tisdell, 2016). Ethnography was not suitable for
my study because my intention was not to focus on studying a group of people within a
culture. The narrative inquiry focuses on the first-person accounts of experience told in
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story form. Biography, life history, and autobiography are examples of narrative inquiry
(Merriam & Tisdell, 2016). The narrative inquiry was not appropriate for my research.
The main purpose of the phenomenology design is to explore human experiences
from the perspective of participants within a phenomenon (Bloomberg & Volpe, 2019).
Studying human experiences was not my intent for this study. The objective of my study
was to explore strategies US pharmaceutical company leaders used for developing and
implementing successful OI pharmaceutical R&D projects. Therefore, a single case study
design was the most appropriate design for this study.
Population and Sampling
The population sample for this qualitative single case study was five R&D
directors in a single US pharmaceutical company located in the northeast. Participants of
the qualitative single case study included male and female R&D directors who were
chosen through purposeful sampling and were interviewed via WebEx. The choice of
interview method was to make the participant comfortable during the interview and to
transcend geographical barriers. Purposeful sampling is a standard technique used in
qualitative research studies where a researcher selects information-rich cases for the
study that will provide insight and understanding to a phenomenon or topic of interest
(Benoot et al., 2016). The conditions for selecting participants in this study included
R&D directors in a single pharmaceutical company with knowledge and experience with
using OI strategies to implement pharmaceutical R&D projects.
In qualitative research, data saturation is important. Fusch and Ness (2015)
identified that data saturation is necessary when determining the sample size for a study
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and that data gathered must be rich quality data and a dense quantity of data. Saunders, et
al. (2018) posited that data saturation is commonly taken to indicate that, based on the
data that has been collected or analyzed, further data collection and/or analysis are
unnecessary. Data saturation is met when there is no new data being collected, no new
patterns being discovered, and no new coding being conducted (Tran et al., 2016). In a
qualitative research study, once data saturation is met, the sample size will be set. In this
study, I interviewed five participants to ensure data saturation. I ensured data saturation
for this study by collecting comprehensive data and identifying essential themes of the
open innovation capability framework (OICF) by interviewing five participants who are
R&D directors and have met the study conditions. Saunders, et al., (2018) concluded that
saturation should be consistent with the research question (s), the theoretical position, and
the analytic framework adopted for the study.
Ethical Research
Throughout the research process, I focused attention on the application of ethics
to the research process. Sobočan et al. (2019) said ethics when viewed broadly are
intrinsic in the research process, from the decision about what to study and how to study
it, through data analysis and dissemination of the research ﬁndings. The principles of the
Belmont Report such as autonomy, beneﬁcence, and justice were maintained through
informed consent, non-deception, the prevention of psychological or physical harm,
privacy, conﬁdentiality, and a commitment to collecting and presenting accurate research
ﬁndings. The three major components of the Belmont Report (respect for persons,
beneficence, and justice) serve as an ethical framework for research involving humans.
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Each participant enrolled in my study signed a written consent form (see
Appendix C.) to take part in the interviews which is the data collection phase of the
research. Moreover, I followed the protocols of the Belmont Report and ensured that the
study participants had a full understanding of their part in the study. I provided a copy of
the consent form before the data collection to allow participants time to review the form
and understand the study. Nusbaum et al. (2017) said potential participants should be
provided a copy of the consent form before or after the consent meeting, which they will
receive via email. Nusbaum et al. argued participants supported this commonly used
approach because it provided individuals with more time to read the consent form.
Privacy and confidentiality were further protected by coding the interview
sessions with all participants and organizations. Coding the interview sessions will
protect the identity and confidentiality of all participants. Researchers have the
responsibility of conducting ethical research and safeguarding the confidentiality of all
participants (Miracle, 2016). Participant names and identifiers will be saved in an
EXCEL file under a coding system to guarantee confidentiality.
Participants were informed that they may withdraw from the study at any time
without penalty. The time and location of the interviews were at the convenience of the
participants. Each participant interview was given an allotted time of 1 hour, but time was
increased or decreased depending on the responses given by each participant. Participants
were able to disengage from the interview at any time without consequences by
contacting me through email or by phone.
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For participants that provided interviews a twenty-five-dollar Amazon gift card
was provided for their time. Kelly et al. (2017) conducted an experiment with a nationally
representative sample to test the impact of different incentive types and amounts on
willingness to participate in a qualitative interview. Kelly et. al. study findings suggested
increased participation with incentives as low as twenty-five dollars. Researchers may
increase the study participation by providing a least the minimum incentive.
Each research study comes with its own set of specific ethical issues and in this
case, the study was conducted at my employer. The participants do not report to me and
are also at a level above my pay grade. Furthermore, the participants were located hours
from my current location, so I do not know them personally. The data from the study is
stored on OneDrive and my personal computer. All data storage will be password
protected and saved for five years.
The participating research site signed a letter of organizational cooperation
permitting participation (see Appendix A). Once the IRB approved the study, I sent
invitations to the study participants through email and answered any questions the
participants had about the research. All participants read and signed an informed consent
form before the interviews.
Data Collection Instruments
The primary data collection instrument for the study was the researcher. I used
semistructured interviews for data collection. A well-designed semistructured interview
should ensure data are captured in key areas while still allowing flexibility for
participants to bring their own experiences and perspectives (Barrett & Twycross, 2018).
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The interviews for this research consisted of 10 open-ended questions, which were
intended to uncover the viewpoints and experiences of five pharmaceutical R&D
directors with experience successfully developing and implementing OI pharmaceutical
R&D projects.
I used a voice recording device to document the interviews with each participant.
Heath et al. (2018) suggested recording interviews, then transcribing the interviews
verbatim, and storing the interviews as a word document for analysis. Recording
interviews, then transcribing the interviews verbatim facilitate accurate data collection.
All data files were anonymized and stored securely.
After the completion of each interview, I had the voice recording transcribed.
Member checking was performed by emailing the interview transcripts, interpretations of
the data from the interview, and the conclusions of the data from the interview to the
participants. Marshall and Rossman (2016) proposed member checking can be used to
improve the accuracy and validity of the interview data. The follow-up interview process
included the participants’ evaluations of my understanding of the interview discourse for
accuracy.
Along with accuracy the reliability and validity of the data collection instrument
were improved through this member checking process. Furthermore, public company
documents and other external website content were used in the data collection process to
corroborate the data collected with interviews. Bloomberg and Volpe (2019) suggested
the combination of interview data with public company documents and external website
content can improve the validity of the data.

65
Upon the approval of the study from the Institutional Review Board (IRB), I
emailed an invitation to potential participants along with an informed consent form
clarifying the risks and benefits of participating in the study. I was also available to
answer any questions the participants had about the study. The allotted time for each
interview was approximately 1 hour, but more or less time was needed depending on the
participant’s responses. The interviews were conducted via WebEx (synchronous
computer-mediated communication). Merriam and Tisdell (2016) proposed synchronous
computer-mediated communication will help overcome the geographical barrier of
participants and researchers.
The participants for this study were several hours away so the use of synchronous
computer-mediated communication made it more cost-effective and timelier to collect the
data. Lo Iacono et al., (2016) suggested synchronous computer-mediated communication
is a system that provides users with a way to send voice and video across the internet via
a synchronous (real-time) connection. The use of this technology provided convenience
because the interviews of participants at a distance were conducted without the expense
of travel. The time for the interviews was at the convenience of the participant. Another
advantage of the synchronous computer-mediated communication was that a venue did
not need to be secured. All the participants answered the same 10 interview questions
(Appendix D), which helped to explore the experiences of each participant in answering
the central research question. The data obtained helped uncover themes that
pharmaceutical R&D directors have experienced while successfully developing and
implementing OI pharmaceutical R&D projects.
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After each interview, I transcribed, coded, and analyzed the data. The data
collected from the interviews are stored in a computer file on OneDrive cloud storage, a
USB flash drive, and my computer hard drive and will be saved for 5 years. Each device
is password protected and only I have access to the data. After 5 years, I will destroy the
flash drive along with any other resources and documents. Data collection was essential
to gathering the relevant data needed to answer the principal research question “What are
the strategies that US pharmaceutical company leaders use to develop and implement
open innovation R&D projects?
Data Collection Technique
Researchers can gather case study evidence from many sources. Yin (2018)
proposed that interviews, documentation, and archival records are three sources of data
that can be used for case study research. This qualitative case study included the data
collection instruments of semistructured interviews, public company documents, and
external website content intended to uncover the viewpoints and experiences of
pharmaceutical R&D directors with experience successfully developing and
implementing open innovation (OI) pharmaceutical R&D projects. Belotto (2018)
suggested semistructured interviews allow the researcher to ensure that the same core
information is elicited from each participant while providing the flexibility to probe more
deeply into the rich descriptions of experiences that participants share.
I used the following procedure to schedule the semistructured interviews.
For each participant, I scheduled a date and time for each interview based on the
agreement obtained from the participant. Participants of the study answered the same 10
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questions about their experiences in successfully developing and implementing OI
pharmaceutical R&D projects. The 10 interview questions were asked via synchronous
computer-mediated communication with the five pharmaceutical R&D directors in a
single pharmaceutical company. Each interview was allotted one hour; however, more or
less time was needed depending on the responses of the participants. The interviews
included a question on what strategies the pharmaceutical R&D directors used to develop
and implement OI pharmaceutical R&D projects. The interviews of each participant were
via synchronous computer-mediated communication (e.g. WebEx) and their responses
were recorded using a digital voice recorder. Also, for confirmability and to use
methodological triangulation I collected data from public company documents and
external website content relevant to the research question.
The analysis of the data collected uncovered strategies that could help
pharmaceutical R&D directors develop and implement open innovation (OI)
pharmaceutical R&D projects more efficiently. Data collection techniques have
advantages and disadvantages for qualitative research studies. Doody and Noonan (2013)
posited advantages include (a) gaining insight and context on the topic, (b) gaining an
understanding of a topic from a participant’s experience and knowledge, and (c) gaining
useful information for the research study. The disadvantages of collection techniques
include (a) intrusiveness to the participant, (b) time-consuming to both participant and
researcher, (c) expensive data collection methods, and (d) may be susceptible to bias.
Once I received approval from the Institutional Review Board (IRB), the
following procedure for the research study was followed. Contact information was
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collected from the participants of the study. Initial contact was made with the participant
to clarify any questions or concerns they may have about the study and the informed
consent form. The informed consent form was collected through e-mail. I scheduled the
interviews and then interviewed the participants via synchronous computer-mediated
communication. Upon completion of the interviews, the data voice files were transcribed
and shared with the participants to confirm the accuracy.
Member checking is the process by which participants check and approve the
understanding of the researcher of the data collected from the interview (McGrath et al.,
2019). I performed member checking with the participants after the interviews. If the
participants made any changes to the transcription, I notated the changes on the initial
transcript. I then imported the transcript into the data analysis software. Yin (2018)
suggested computer-assisted tools can help analyze qualitative data. The computerassisted tool can help novice researchers code and categorize large amounts of data
(Saldana, 2016). I used data analysis software to help identify themes and categories from
the data.
Data Organization Technique
The organization of data was a critical aspect of examining and understanding
data in the study. The iterative inspection and organization of data are necessary in a
qualitative case study (Castleberry & Nolen, 2018). I was the primary data collector of
information from each participant of the study. I classified each participant by a letter and
number, which will be documented and coded in a Microsoft Excel spreadsheet for
confidentiality. Confidentiality and anonymity can be reached within a study by using a
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coding system for each participant (Clark & Vealé, 2018). The data collected were
recorded, examined, transcribed, and stored on OneDrive (cloud storage), a flash drive,
and my personal computer. All devices are password protected and only I have access to
the data. To safeguard the rights of participants, confidential data can be secured and
stored (Clark &Vealé, 2018). After 5 years, I will destroy the flash drive along with any
other resources and documents used in the study.
Data Analysis
Qualitative case study methodologists can use up to six sources of evidence for
their research including documentation, archival records, interviews, direct observations,
and physical artifacts (Yin, 2018). The major strength of the case study research is the
opportunity to use multiple sources of evidence. I conducted a qualitative single case
study, which included participant semistructured interviews, public company documents,
and external website content. Fusch et al., (2018) suggested case study researchers should
use multiple sources of data to improve the quality of their research. Data triangulation
adds depth to the data that are collected. Yin (2018) posited that there are no set guides to
use to begin analyzing qualitative data, therefore, all data analysis of the single case study
should use a broad analytic approach. Castleberry and Nolen (2018) suggested a model of
qualitative data analysis outlined in ﬁve steps: compiling, disassembling, reassembling,
interpreting, and concluding.
The qualitative data analysis is an iterative process and preferably should be
performed concurrently with data collection (Miles et al, 2020). Miles et al. (2020)
posited researchers should cycle back and forth between thinking about the existing data
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and generating strategies to collect new data. Miles et al. presented three streams of data
analysis (a) data condensation, (b) data display, and (c) findings and verification. After
each interview, I transcribed the data and familiarized myself with the interview
transcript.
Raskind et al. (2019) suggested many researchers used verbatim transcripts as the
primary data source. I created a matrix using the 10 interview questions and the responses
from each participant to get started. Raskind et al. reported that 20% of researchers
reported using matrices during analysis. Matrices were used to compare codes or themes
across participants (Raskind, et al., 2019). I manually went through the transcripts to
identify similarities and differences between participants and then tried to identify themes
from the participants' responses.
Next, I uploaded the transcripts into a computer-assisted software program (e.g.
NVivo ) to help identify themes to understand the data and generate codes. After
collecting relevant content from company documents and external websites I followed
the same iterative process to identify themes. These main themes provided strategies
pharmaceutical R&D directors have used to successfully develop and implement OI
pharmaceutical R&D projects.
The purpose of the data analysis was to uncover themes that can answer the
research question of this qualitative single case study. Discovering the topical similarities
and differences could potentially inform the answer to the overarching question. The data
analysis process of a qualitative study is an important step. Saldana (2016) suggested
using a provisional list of codes related to the conceptual framework to start the data
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analysis. I used 23 codes from the OICF and some keywords identified during interviews
with participants to begin coding the interviews. To provide direction and organization to
the data analysis I used the 23 codes that compose the high-level categories of the OICF
to begin my analysis. Researchers need to analyze data to uncover significant patterns
and themes that answer the main research question of the qualitative study (Yin, 2018). I
consolidated the data collected into sections similar to the sections in the literature review
related to the OICF framework: strategic alignment, governance, methods, IT, people,
and culture.
I used NVivo, a qualitative data analysis software, to help organize and code the
data analysis in this study. Researchers can use software like NVivo to identify patterns
and themes in the data that may otherwise be overlooked (Davidson et al., 2017).
Davidson et al. (2017) suggested NVivo helps researchers to see into the depths of a
qualitative research project. The strengths of using the NVivo software included working
with very rich text-based and/or multimedia information, where deep levels of analysis
on small or large volumes of data were required. I used the NVivo software to verify the
patterns and themes uncovered through the manual analysis of the data and the sections
described in the literature review. The connection between the methodology, the
literature review, and the findings of the study is the OICF. I used the OICF as the lens to
analyze the data.
Reliability and Validity
The significance of a qualitative research study is contingent on the level of
confidence others have in the findings of the researcher. Qualitative research
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methodologists ensure trustworthiness in a case study approach by demonstrating
credibility, confirmability, transferability, and dependability (Yin, 2018). Trustworthiness
in qualitative research includes both the validity and reliability dimensions (Quintão et.,
2020). The following sections provide information on the use of case study procedures in
a qualitative research study.
Reliability
Reliability refers to how qualitative methodologists will address the dependability
of the study results. Some of the ways a qualitative methodologist enhances the
dependability of a study are member checking of data interpretation, transcript review,
using an interview protocol, and reaching data saturation. Qualitative researchers produce
findings not derived using statistical procedures or other means of quantification. Cypress
(2017) posited qualitative researchers use naturalistic inquiry to understand a
phenomenon in a context-specific setting. A qualitative research methodologist does not
attempt to manipulate the phenomenon of interest.
Qualitative research methodologists ensure reliability based on consistency and
care in the application of research practices. In this qualitative study, I followed the
interview protocol for each participant to ensure each participant was asked the same
questions. Furthermore, the participants had experience developing and implementing
open innovation (OI) pharmaceutical projects. To establish trust and confidence in the
findings of the research, rigor will be necessary to confirm the consistency of the study
methods. Reliability and validity should be taken into consideration by qualitative
inquirers while designing a study, analyzing results, and judging the quality of the study
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(Belotto, 2018). The foundation for the reliability of the research study is determined
through the dependability of the research process, which included the research question,
data collection method, data interpretation, and the instrument (me).
Merriam and Tisdell (2016) suggest that reliability in research design is based on
the assumption that there is a single reality and studying repeatedly will yield the same
results. In addition to the semistructured interviews of the five participants, I used
documentation to methodologically triangulate the data collected from semistructured
interviews, and finally, I performed member checking after each interview to ensure the
accuracy of the results.
Dependability
When researchers follow research procedures, they improve the consistency of
data collection. When the audit trail of a researcher is duplicated by another researcher,
dependability will occur (Connelly, 2016). I ensured dependability by having participants
check the information gathered through member checking and confirm the accuracy of
my understanding. Gaus (2017) explained member checking is a participant’s validation,
which confirms the data, interpretations, and conclusions of the researcher with the
interview participant. Member checking is imperative and a common way to ensure the
truthfulness and authenticity of the data (Fitzpatrick, 2019). I performed member
checking after each interview to confirm my understanding.
Validity
The qualitative research methodologist seeks to ensure validity by establishing
trust in the inferences that they put forth. Validity refers to the accuracy of the research
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findings. Validity consists of two types of validity, internal and external (Fitzpatrick,
2019). Gaus (2017) posited internal validity is the extent to which the findings can be
interpreted accurately and in a qualitative study, internal validity is most important.
Sound internal validity is established by using multiple sources of data collection (e.g.
interviews, document analysis, etc.) and interviewing multiple sources of people and
triangulating their stories within the case (Gaus, 2017). An assessment of data by the
researcher for consistency among the participants of the study will help achieve internal
validity within the qualitative research study (Yin, 2018).
Qualitative methodologists can use purposeful sampling in qualitative research so
that the participants are the appropriate people to respond to the intent of the research.
Fitzpatrick (2019) suggested that purposeful sampling requires the selection of
participants who know about the research topic. I collected information from multiple
sources, which included conducting interviews, company documents, and external
website content to address validity.
The interviews conducted by me were consistent for all participants using an
interview protocol (Appendix D). Furthermore, I will improve internal validity with the
use of member checking and triangulation. Member checking is the process of seeking
participant validation and the most important way to rule out the possibility of
misinterpreting the meaning of the participants' interviews (Gaus, 2017). Member
checking was an important way of identifying my biases and misunderstandings of what I
heard. Furthermore, to increase the credibility of the findings and reduce bias, researchers
try to establish triangulation by searching for convergent results from multiple and
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different sources of data, multiple qualitative methods, or multiple researchers (Gaus,
2017).
Credibility
Credibility is an accurate and truthful portrayal of a participant’s lived
experience (Cypress, 2017). The credibility of the study is assurance in the truth
of the findings. A qualitative research methodologist can enhance credibility by
member checking of the data interpretation, participant transcript review,
triangulation, and an interview protocol (Gaus, 2017). Demonstrating qualitative
credibility ensures the reviewers that the researcher addressed the findings from
the perspective of the participants (Fitzpatrick, 2019). I improved the credibility of
this study with participant transcript review, member checking, triangulation, and
an interview protocol.
Confirmability
A qualitative research methodologist can enhance the confirmability by
ensuring that the results can be confirmed or supported by others. The researcher
may conduct member-checking with study participants to ensure confirmability
(Belotto, 2018). Confirmability is the degree findings are consistent and could be
repeated. This is analogous to objectivity in quantitative research. Qualitative
researchers keep detailed notes of all their decisions and their analysis as it
progresses (Connelly, 2016).
I asked probing questions during interviews and followed up with
member checking. Cypress (2017) suggested data triangulation should also help
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ensure confirmability. Data saturation was obtained in this qualitative single case
study by interviewing five participants until no new themes were evident. The
sample size of this qualitative single case study was determined when data
saturation was met (Fusch et al., 2018). I made sure the sample size was
sufficient to reach data saturation and address the research question.
Transferability
The nature of transferability is the extent to which the findings can be
useful in other contexts. The reviewers of qualitative research determine the
applicability of a researchers’ findings to their circumstances (Bloomberg &
Volpe, 2019). Qualitative methodologists can support the study’s transferability
with a rich, detailed description of the context, location, and people studied (Yin,
2018). Qualitative researchers need to provide a vivid picture that will inform
and resonate with the reviewers (Amankwah, 2016).To improve the
transferability of the findings I meticulously adhered to the data collection and
analysis techniques for the research design, used an interview protocol and
ensured I reached data saturation. Furthermore, I used a notebook to document
my thoughts, reflections, and decisions regarding the study to further improve
the ability to make the study transferable.
Transition and Summary
In Section 2, I described how I conducted a qualitative single case study to
explore strategies US pharmaceutical company leaders use for developing and
implementing successful OI pharmaceutical R&D projects. I audio-recorded
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semistructured synchronous computer-mediated communication interviews to collect data
and explore the experiences and strategies of the participants. In addition to
semistructured interviews, I reviewed public company documents and other external
website content to triangulate data. I used purposeful sampling to select five R&D
directors in a single US pharmaceutical company located in the northeast. Before the
collection of data proceeded, I obtained permission from Walden University’s IRB to
execute data collection. Once transcriptions of interviews were complete, I used NVivo to
uncover common themes and patterns in the study. Also, I explained the purpose
statement, role of the researcher, population and sample size, research method and
design, ethics, data collection instrument and techniques, data analysis, and the reliability
and validity of the study. In Section 3, I incorporate the presentation of findings,
applications to professional practice, implications for social change, recommendations for
action, and recommendations for future research. This is followed by reflections and
conclusions.
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Section 3: Application to Professional Practice and Implications for Change
Introduction
The purpose of this qualitative single case study was to explore the strategies that
US pharmaceutical company leaders use to develop and implement OI R&D projects.
Five R&D directors in a US pharmaceutical company located in the northeast who had
successfully implemented OI strategies were interviewed via NVivo. The five R&D
directors discussed four major themes: OI roles and responsibilities, business and OI
strategy alignment, leadership attention, and OI decision making.
Presentation of the Findings
The overarching research question in this study is: What are the strategies that US
pharmaceutical company leaders use to develop and implement OI R&D projects? I used
pseudonyms to anonymously identify the five participants as P1, P2, P3, P4, and P5. Four
major themes emerged during data analysis to indicate strategies US pharmaceutical
company leaders use to develop and implement OI R&D projects. The following
discussion is organized around these four themes (see Table 1).
OI is an established approach to improve innovation performance, but many
organizational leaders have unsuccessfully embedded strategies permanently in their
innovation processes.
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Table 1
Major OI Implementation Themes

OI roles and
responsibilities
Business and
OI strategy
alignment
Leadership
attention
OI decision
making

Total
frequency of
themes from
Interviews
108

% of themes
occurrence

101

27

87

23

81

21

29

Table 2
Frequency of Major Themes for Each Participant
Themes

P1

P2

P3

P4

P5

OI roles and
responsibilities
Business and
OI strategy
alignment
Leadership
attention
OI decision
making

33

28

9

22

16

16

44

3

15

23

20

28

6

12

21

22

31

4

11

13

OI Roles and Responsibilities
A leader needs to clearly define OI roles and responsibilities in their organization
to ensure the successful adoption and implementation of OI strategies. In this study, five
directors in a US pharmaceutical company shared their experiences regarding the
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implementation of OI pharmaceutical R&D projects. The five participants described the
roles and responsibilities of many of the staff involved in the process. Participants
described OI actors as scouts, scientists, business development staff, alliance
management, integration management, and academic researchers. P1 said:
We involve all the department stakeholders that are important for the success of
the project. Projects are selected at different stages of development and each
project is unique so there is no one size fits all. Aside from the scientists, many
departments often need to be involved to some degree e.g. patent attorneys, tax
accountants, etc.
Each project is unique and may require different capabilities. Therefore, it is
important to have staff involved in OI projects with defined roles and responsibilities.
Individual competencies of team members, including knowledge, skills, and attitude are
of the greatest importance to the success of the OI project. OI strategies require leaders to
find, identify, select, and evaluate projects that are aligned with overall business
strategies and then integrate projects seamlessly into the organization.
All interview participants (P1-P5) stated that to find and identify new OI projects
aligned with high-level strategies, they implemented search and evaluation teams within
the R&D organization. Search and evaluation teams are integral to the success of finding
the right projects. They are scouts for the organization that assist in implementing
strategies defined by research units. Zynga et al. (2018) said scouts identify advances in
science and technology that can be useful for the company. Hosseini et al. (2017) said
scouts and idea connectors are complementary roles that are of high importance in terms
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of creating successful OI outcomes. Strategies involve either directed searches in a
specific technological area or via an undirected search for new technological
opportunities.
All participants stated search and evaluation teams are external facing the
organization’s R&D department. The role of the employees in search and evaluation
teams is looking for specific external partnering collaborations, licenses, or acquisition
opportunities, typically in the preclinical or discovery space across a span of technologies
or therapeutic areas. P1 said: “The employees in search evaluation are often former
researchers; therefore, they understand the needs and the technologies. The staff in search
and evaluation teams have a specific scientific skill set that helps to serve their purpose”
P5 stated:
I start with a clear understanding of our internal strengths and the areas we have
gaps. If I understand our strengths and weaknesses accurately, then this
information helps to define the space broadly and provides direction to external
innovative opportunities.
P5 said: “The specific areas that I am scouting externally are technologies around large
molecule discovery and development, and digital platforms.” P2 said: “The search and
evaluation team is a global group that helps all the research units find projects. After the
search and evaluation team find the projects, then it is up to the business development
department to execute a contract.”
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Search and Evaluation Team Strategy
Search and evaluation teams in the pharmaceutical industry use several strategies
to find projects that are aligned with the overall business strategy. Some of the strategies
scouts use to search and find projects include their personal and professional networks,
literature searches, academic institutions, patent data, and conferences. Zynga et al.
(2018) said scouts are very important to developing a robust open innovation program. In
addition to helping pharmaceutical leaders discover novel technology, scouting
techniques, data mining, data access systems, and information technology support the
absorptive capacity of firms (Zoebel & Hagedoorn, 2020). The absorptive capacity of the
firm is the leader’s ability to recognize the value of new technology and then acquire and
integrate the asset into operations and apply it in the development of new products.
When leaders implement OI strategies, they must create additional processes to
deal with the scale and scope of external inputs. The ability to be able to accommodate
these additional processes to evaluate new technologies and innovations is a firm’s
absorptive capacity. An external technology scouting team commonly uses an open
search method to facilitate finding innovations (Wang & Quan, 2019). Organizational
leaders must develop processes to select the most valuable ideas and integrate them with
their existing knowledge base (Rasiah, 2019). Having enough absorptive capacity in a
firm is critical to successfully implementing open innovation strategies.
Networks: personal and professional. Networking is an important method that
scouts use to find new technologies. Scouts and scientists are key individuals in open
innovation capability and improve the chances of finding novel technology and
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exploiting it (Rasiah, 2019). Scouts help connect individuals, firms, and organizations to
support innovations openly across innovation systems. Hosseini et al., (2017) discussed
peer leadership in the OICF. Hosseini et al., (2017) suggest peer leadership helps ensure
OI progress and success despite the absence of a formal hierarchy. I would argue that
networking is a form of peer leadership because networking is an informal method to
connect with others. P5confirmedthe importance of peer leadership commenting:
Scientific connections are the other place where ideas and projects are discovered.
The scientists that are in the search and evaluation team and all the PhDs that are
all within the research unit have connections. This staff has contacts from the
universities where they received their PhDs. Scientists use these networks to bring
forward ideas that look promising.
Furthermore, P5 said:
Our group is externally facing, those of us who are externally facing through
going to conferences and staying current with the literature learn who are the key
collaborators and subject matter experts and leaders in the field, whether they are
academic, startups, or pharma peers.
Conferences and meeting attendance. Search and evaluation scouts attend
conferences and scientific meetings where they can network and find new technologies.
Conferences such as the annual BIO International Convention play a critical role in the
pharmaceutical industry leaders’ sources of information and networking. The conferences
are valuable sources of information, industry trends, and current news and provide
opportunities for interactions between industry participants searching for new
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technologies and opportunities. Professional conferences facilitate the convergence of
these informal leaders with mutual interests that may increase the occurrences of
collaborations.
In addition to numerous networking events, many conferences also facilitate oneon-one meetings. The one-on-one meetings are organized scheduled interactions called
partnering meetings. Partnering meetings are scheduled in advance of the conference so
the interactions between participants are deliberate. Scheduling the partnering meetings is
enabled through an online portal provided by the meeting organizers that is accessed on
the conference’s website. The partnering meetings typically last only 30 minutes.
Although the duration of the initial meeting is short, the relationship between the parties
may continue after the initial interaction. P1 said:
We attend conferences such as JP Morgan and the BIO conferences, those are big
partnering conferences that offer a lot of networking opportunities. The
conferences offer one-to-one partnering sessions that we can register for. These
partnering sessions are an opportunity to meet with company representatives that
want to pitch their technologies. Each company will meet with the business
development staff and search and evaluation scouts at these conferences for 30
minutes. Each company has representatives who provide a brief presentation of
their technology and value proposition. Some of these presentations are
unproductive and others lead to professional relationships. If the technology is
early in development, we may stay in contact with company leaders and check
with them every six months to a year to monitor their progress. For the
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technologies that are further in development, if we are interested, we may start a
smaller research agreement together and then if it is successful, we build upon it.
Not all conferences have partnering meetings.
The J. P. Morgan Healthcare Conference referred to by P1, is a premier event for
conferences and do not have centrally organized partnering sessions. P1 noted with the J.
P. Morgan Healthcare Conference business development, scouts, and executives arrange
meetings with the innovators. Nonetheless, conferences are gathering forums for large
numbers of participants interested in a similar topic. Therefore, there is an increased
opportunity of meeting other participants who may have an interest in partnering.
Hosseini et al. (2017) OICF did not specifically address conferences and scientific
meetings as sources of innovation. However, Hosseini et al. did reference boundary
spanning and social brokerage as important aspects of OI implementation. Individuals
with social brokerage capabilities can connect the right actors that would normally not be
in contact and ensure that external ideas and knowledge are utilized. Conferences enable
social brokerage between individuals and organizations.
Another important concept noted in the OICF is boundary spanning, which is the
ability of individuals to manage heterogeneous information and clearly articulate the
value proposition. Boundary-spanning enables cognitive distance to be overcome and
mutual understanding established between partners within and outside organizational
boundaries (Hosseini et al., 2017). Conferences promote boundary-spanning interactions
between internal and external the participants. Social brokerage and boundary spanning
are some of the components of the high-level OICF capability of people.
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Literature search. Scouts’ other method for identifying projects is by searching
the scientific literature and consulting with thought leaders. Recent scientific literature
and thought leaders can provide direction for the scout’s searches. P1said: “In addition to
the big conferences, scouts and scientists also scour the scientific literature, looking for
technologies and projects that fit our business strategy. The scouts use the literature as
leads to find innovations and subject matter experts. In support of the OI business model,
P1 said:
Well, there's no way that the organization has all the resources to do everything
internally. We need to be realistic and understand we cannot be the best at
everything. There are people out there that are better than us in certain areas and
maybe ahead of our organization in the development timeline. When these
circumstances exist, we may go outside the organization.
Universities/academia. Another source of innovation that scouts use to identify
new projects is academic sources. P4 suggested search and evaluation scouts visit with
researchers in academia to identify potential projects that are aligned with our goals and
therapeutic areas. To participate in the program the researcher must sign an agreement
that explicates the terms of the partnership. P4 said:
We intentionally recruited staff from outside the company because we needed
staff that thinks differently. With the agreement we have with academics there is
very much an open sharing of information. Just as we run a drug discovery and
development program we would envision needing to prove or disprove the
hypothesis at every step of the way and that is very much an open dialogue
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around the knowledge the academic principal investigator brings to the project
regarding the biology and the drug target.
P4 also said:
Our researchers can go in and work in the academic institutions’ labs, and the PIs
can come in and work in our labs as well. We share the data in real-time, and we
have joint project team meetings where we problem solve, and we review the
data. The academic institution becomes an extension of the company to share
knowledge and improve the chances of producing a product.
P4 suggested:
The approach I would call a passive approach is when we put out a call for
proposals, through our network community, once or twice a year, where we state
the type of project we are interested in and the stage at which the research needs
to be at. The interested party would also need to agree to disclose information
requested by the company related to the project for due diligence. The other
approach is a more active targeted approach, and this is where our scouting team
focuses a lot of their activities. The scouts deliberately go out and search for
academic principal investigators (PI) who they know are working in research
areas of interest to us. The scouts then build relationships with these PIs and see if
there is a research project, they can work on together.
To succeed in OI, organizations must develop capabilities related to knowledge
exploration, retention, and exploitation. Hosseini et.al. (2017) does not specifically
mention academia in the OICF as a source of innovation but addresses Methods as one of
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the high-level capabilities. Hosseini et.al. Methods capability includes the adoption of
appropriate tools, techniques, and practices that support knowledge capabilities and
integration. Establishing collaborations with academia could be considered a strategy.
Universities scientists produce science-related knowledge that is the output of
fundamental research in basic sciences. Researchers in universities can potentially
generate radically new technologies (Colombo et al., 2021). University researchers
possess state-of-the-art technical knowledge that is generated by applied research
programs and has a broad range of applications in different technological areas.
Scientiﬁc knowledge in academia is potentially a valuable input to ﬁrms’
innovation activity but is often generated with little consideration for its direct
commercial application. Researchers in academia can be thought of as an extension of the
company’s labs and workforce and therefore, relationships with academia could
potentially expand the company’s absorptive capacity (Tajudeen et al., 2019). Academic
researchers’ efforts are often not generated with a commercial product in mind; therefore,
a pharmaceutical company leader would need a process to harness the researchers' efforts
directing them toward the intended endpoint of developing a therapeutic for a particular
disease. The pharmaceutical managers in this single case study use an agreement with the
university and PI to help direct the research efforts toward the intended therapeutic area.
The relationship with academia has been successful. P4 stated “After 10 years,
this collaboration with academia has been fruitful.” P4 stated the open innovation model
with the universities started as an experiment and has been successful in the 10 years the
program has been in place:
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External knowledge exploration refers to methods to develop potential absorptive
capacity. Because academia is an extension of the company’s labs this agreement with
academia expands the organizations networks and their available absorptive capacity
(Burcharth et al., 2017). The complementary nature of internal and external knowledge
exploration requires an integrative approach when implementing OI.
Business and OI Strategy Alignment
The second theme identified was business and OI strategy alignment which is one
of the components of the OICF strategy alignment. To benefit from OI, organizational
leaders must align their OI strategy with their business strategy. Organizational leaders
who are searching for opportunities have different priorities than organizational leaders in
a defensive mode (Hosseini et al., 2017). Firms searching for opportunities want to
balance their search breadth, the number of sources and channels used to search for OI
projects, and the intensity of each effort (Cammarano et al., 2019; Naqshbandi et al.,
2019). Absorptive capacity has been thoroughly researched and therefore R&D leaders
should be aware of the negative impact when their organization reaches an imbalance of
search breadth and intensity that results in decreasing productivity. This inverted-U
relationship between search breadth and intensity is because the absorptive capacity is
exceeded.
To prevent the problem of exceeding absorptive capacity from occurring, the
R&D leaders need to have a clear business strategy. P1 said:
Our job is to find the science and technology that is considered the best science
with our internal search and evaluation partners. Then to either bring the science
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into the organization through a license or to work collaboratively with the partner
organization.
The overall strategy needs to be communicated by the leaders. Barham et al.
(2020) research findings showed that there is a positive correlation between management
support of OI and the possibility of successful adoption of OI. Moreover, Barham et al.
results offered insight on some of the dynamics of how management support affects OI
adoption. P1’s comment suggests that the senior leaders in this organization have
provided a clear strategy and support for OI to employees. Barham et al. posited
employees’ perceptions of management support for open innovation will correlate
positively with ﬁrm adoption of open innovation. The provision of resources to support
the OI strategy can demonstrate the leaders' support.
To identify projects aligned with the high-level strategy the leaders of the
organization implemented search and evaluation teams within the R&D organization. The
search and evaluations team’s role are described in an earlier section, roles, and
responsibilities. The organizational leaders have demonstrated support of OI through the
implementation of the search and evaluation scouts. The scouts drive the strategy by
implementing the action plans provided by the management of each research unit.
Moreover, each research unit has a triad which is the three leaders that are
responsible for each research unit, research, development, and commercial. The leaders
of the research units provide a more detailed strategy for the scouts. The triad explicates
the strategy for the therapeutic area of interest and the potential platforms and
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technologies of interest. The elucidation of the strategy provides a focus for the scouts’
searches. P1 stated:
Business development reports to the Chief Business Officer (CBO) this
department is separate from the R&D organization. Each Chief Scientific Officer
(CSO) in the research units creates its strategy. The CSOs of the research units
create a strategy in conjunction with, the Chief Development Officer and the
president of the business unit and these three leaders need to be aligned with
regards to the early-stage assets that will be developed and commercialized within
the organizations business unit. The organizational structure promotes alignment
throughout the organization.
Furthermore, P1 said:
We must prioritize our portfolio because each research unit only has a finite
budget to spend on their assets. The leadership of the research units goes through
an annual prioritization exercise where they look at the budgeted dollars available
and all the programs and decide which programs they can afford to pursue.
P1 said:
Since it is unlikely, we can afford all the programs, sometimes the leaders will
look to partner one of our assets with someone else. There is no one size fits all
for R&D projects. It is important to consider risk and reward. The circumstances
are going to be unique for each asset and therapeutic area.
P1 stated:
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The research and development teams and the commercial teams need to have their
goals aligned. If the business unit has no interest in the research deal or the
program is not commercially viable then the business unit will not want to
allocate a budget to buy the asset from the research unit. This is a deal that should
not be executed.
P2 suggested the importance of teamwork: “We need to have a mentality to support open
innovation working together and collaborating to take advantage of science beyond our
walls.”
Hosseini et al. (2017) confirmed the importance of the organization's strategic
alignment suggesting the high importance of an organization’s strategic alignment
regarding OI. The strategic alignment in this pharmaceutical organization seems to be
very important for implementing OI based on the interview data. Hosseini et al. indicated
that contextual factors strongly impact an organization’s strategic orientation. In this
single case study, the context is the US pharmaceutical industry where leaders are always
looking for new opportunities to improve patients’ lives.
Leadership Attention
Leadership attention is the third theme identified in this study. Leadership
attention is one of the components of the OICF high-level strategy culture. Employees’
perceptions of management support for OI will correlate positively with ﬁrms adoption of
open innovation (Barham et al., 2020). Hosseini et al. (2017) proposed in the OICF that
the level of leadership commitment and attention impacts the effectiveness of OI. Senior
management must create a climate conducive to OI. The leaders at all levels of the
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organization must articulate OI goals via written and spoken communication. Hosseini, et
al. suggested sharing success stories with the employees is one technique that can be used
to encourage employees to actively search outside of the organization for new ideas and
technologies.
By implementing appropriate incentives, senior management can also foster
employees’ engagement throughout different hierarchy levels in OI activities. Incentive
structures that foster acquiring innovation from external sources can support moving
from a NIH to a proudly-found-elsewhere (invented anywhere) attitude (Hosseini et al.,
2017). Senior management providing metrics for OI implementation can also be an
effective method to engage the employees and encourage their OI participation.
P5 stated:
First, I think my role is important and valued at the corporate level. So
organizationally I am part of a group that has its explicit mandate to essentially
use open innovation strategies. We are intentionally separate from those core
science and technology lines, so we do have that independence and autonomy to
objectively look at assets and technologies outside of the company so
organizationally that's very supportive in that regard.
Secondly, P5 said:
The CEO articulated quantifiable metrics directly geared towards open
innovation. Specifically, we have quantifiable metrics and goals of projects,
clinical programs specifically that we need to bring in from the outside in any
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given year, so that once again organizationally creates a mandate that will be
assessed on that the whole organization needs to embrace.
P5 also said:
On the cultural, softer side, several individuals are well regarded in the company
and well respected in terms of their scientific and strategic leadership that fully
embrace and promote open innovation programs, both in terms of supporting
funding for these projects from their budget, as well as advocating for projects
that don't necessarily come from inside.
P5 suggested: “I think that it is a lot harder to quantify culture because it is more of a
qualitative cultural piece that also supports the open innovation model. It is not uniform
across the organization, but some individuals drive OI.” P2 stated:
Yeah, so the Oncology department has always been very open to collaborating
with outsiders. I think it is a great strategy and culture that this is how we become
more successful. Using a business model that is including open innovation so that
we can get access to the best talent and technologies and information to move
things forward as quickly as possible and be competitive. So, I think, because the
strategy has always been there, and the leaders are all very supportive. I think the
leaders of the group certainly sets the tone for open innovation culture, and how
we do business.
All the participants comments suggest employees’ perceptions of management support
were very important for OI adoption and implementation.
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OI Decision-Making
The fourth theme identified in the study was OI decision-making which is one of
the four elements composing the high-level strategy of governance in the OICF. Hosseini
et al. (2017) suggested OI experts have highlighted the relationship between culture and
governance among the capabilities related to OI decision-making. Organizations that
have a risk-averse culture may struggle with the implementation of OI projects. Many
decisions need to be made for implementing and an OI strategy.
Also, according to all participants, there is no one size fits all approach, each
project has unique challenges and needs to be managed. Since the participants suggested
that there is no standardized approach to implementing a project and each project has
unique challenges, it would follow that there will likely need to be a greater amount of
decisions. The heterogeneity of the challenges naturally leads to more decisions that need
to be made. For an organization to improve OI performance improving decision making
would be a step in the right direction.
Empowering employees to make a decision is an important step in improving OI
performance. Naqshbandi et al. (2019) suggested that an empowering leadership style
creates an employee involvement climate and empowers employees to involve them in
relevant decision-making. Empowering employees to make decisions will subsequently
enhance a firms’ OI performance.
Decision-making is a very important aspect for the success of open innovation
projects. The time parameter in decision-making is critical; an organization that can
reduce the time between decision and action will have a key competitive advantage.
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P5 said: “In deciding to implement OI we need to have a good idea of our internal
capabilities. If the project can be completed internally then the leaders of the organization
will likely do the project internally.”
The interview participants’ statements are consistent with Lee et al. (2019)
findings that suggest if the employees of the firm possess the capabilities then the leaders
will use closed innovation. If the firm does not have the capabilities, then the leaders will
use an open innovation strategy.
P1 said:
We evaluate our internal team and their capabilities. Is the project something that
we can do successfully on our own? Does the project need to be supplemented
with capabilities that we do not have? Will this project take us longer if we do it
on our own? If another company is 18 months ahead of us in development, we
may want to partner with them to increase the speed to market. Therefore, we may
pay for a collaboration with a partner who is further ahead. So, if an organization
is way ahead, and their science looks as good or better than ours we will likely
partner with them.
Lee et al. (2019) also suggested that when the projects have high complexity that
organizations tend to use OI strategies. Conversely, when the complexity of the project is
low then the organizations tend to use a closed innovation strategy.
P1 suggested:
When we got into gene therapy, there was a lot of early-stage research, but we did
not have the manufacturing capabilities. So, when we committed to doing several
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gene therapy deals, we also had to commit to building a 100 million-dollar facility
to build up our capabilities to manufacture. Also, we needed to hire staff that had
the knowledge to manufacture gene therapy products and scale them up for larger
clinical trials and eventual commercialization.
P5 stated:
We need to justify additional expenses and opportunity costs to work and
collaborate outside of the organization. We need to be able to justify the
investment in OI. If we do not have very strong alignment, and particularly
technical champions from within those expert lines then we have little chance of
getting senior managements’ approval. Also, we need a good internal advocate
(champion) or our chances of success with the OI project are very low.
The decision to advance a project needs to have support from senior management.
When there is a project advocate who can articulate the value proposition of a project
then the project is likely to move forward. If a project does not have an internal advocate
(champion) then it will likely not be successful. Having a project advocate that can
articulate the value proposition of the OI project is essential to the success of OI projects.
P5 suggested for a project to be successful the project needs a champion (advocate).
P5 said:
Scientific thought leaders from within a research unit in the organization need to
understand and be able to articulate the value proposition. The scientific thought
leaders need to be able to help communicate the value proposition up through
leadership to gain approval for the resource allocation to advance the project.

98
In R&D intensive ﬁrms, innovation decisions have a strategic nature and are
critical drivers of a ﬁrms’ competitive advantage (Bogers et al., 2018). Therefore, we
would expect innovation decisions to be more centralized at the top of the corporate
hierarchy. The pharmaceutical organization in this single case study is aligned with
Bogers et al. (2018) study findings. The decision making is at the research unit level
driven by the high-level strategy and portfolio prioritization.
P5 observed:
Without a scientific thought leader that can articulate the value proposition that
there have been several failed attempts, where even some technologies I have
seen that I thought could be incredibly valuable and disruptive for our industry
and potential for the organization but they are a bit outside of the realm of our
traditional capabilities and traditional approaches, and not necessarily filling
incremental gaps in our capability
P5 suggested:
I would say if the gap in skills is too large for a given project this would not be a
good project to pursue. If it would require significant advances along with a large
trajectory of technology and capabilities it may be too far to the side of our core
expertise. If the technology is something so radical to the way we do things today,
that it is seen as too disruptive we may not want to pursue it.
P5 suggested that they have tried to advance some projects that were radical
innovations but were not successful because the supporting technology needed to catch
up. Chimeric antigen receptor is a technology that is very close to personalized medicine
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and can be very effective at combatting certain cancers. The challenge with implementing
this technology was the time and cost to personalize the T-cells. This project failed
internally because of the large gap in capabilities. The leaders of the firm were able to
acquire a company that had the capabilities to get closer to implementing this paradigm.
Kim and Park (2013) said firms incorporating technologically distant knowledge
into their organization are likely to face difﬁculties in assimilating and utilizing the
knowledge. The gap in knowledge from other technological contexts that made it
attractive for high-impact innovation creates problems in integration and assimilation at
the ﬁrm level. Significant effort and expertise on the part of the ﬁrm are required to
assimilate and exploit the knowledge. In this single case study, the leaders of the firm
found it was more cost-effective to partner with an outside organization that possessed
CAR-T expertise. Three of the participants (P1, P3, and P5) suggested projects that are
incremental improvements are less risky and more likely to be pursued if the project
aligns with the business strategy. P3 stated: “We use OI to improve the product for the
patient and to make things better for the patient.”
P5 suggested:
The scouts can use their knowledge of the organization's technical strength to
bolster the case and ultimately progress, any kind of an open innovation project.
Those open innovation ideas that are too far away from our strengths are much
harder for the organization to take the risk to engage in. If we are too far out of
our core alignment and our capability, it's much harder for us to engage in those
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projects that would require a lot more resources. I guess the amount of resources
needed to raise the project would be most of the problem.
An important aspect of risk management and decision making is to evaluate each
project thoroughly before investing too much time and resources. P1, P2, and P4
suggested due diligence for any OI project is important because they have found that
sometimes the science supporting the innovation is not reproducible, an important
decision point. P2 said:
We can understand the science and the mechanism of action, but we still need to
confirm it is reproducible. We have found some projects are not reproducible
internally. So, the project looks great on paper, but when you do your due
diligence you cannot reproduce the results. This will result in not pushing through
a deal. We have terminated deals because we were not able to reproduce the
results internally.
All participants indicated due diligence is an important method to mitigate the financial
risk of the project.
Applications to Professional Practice
I conducted this study to explore the strategies that US pharmaceutical company
leaders have used to develop and implement OI R&D projects. The themes I discovered
from the use of five semistructured interviews, were strategies pharmaceutical managers
should contemplate if they plan to implement an open innovation business model for their
company. Pharmaceutical managers should be particularly attentive to these four areas
when implementing the OI business model: OI roles and responsibilities, business and OI
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strategy alignment, leadership attention, and OI decision making. The findings in this
study have significant applications to professional practice that are relevant to
implementing OI in the pharmaceutical industry to develop novel therapeutics.
Of the four themes discovered, OI roles and responsibilities and business and OI
strategy alignment was revealed more frequently than leadership attention and OI
decision making. The increased frequency of OI roles and responsibilities and business
and OI strategy alignment would suggest that these strategies may be more important
areas to focus efforts. Nonetheless, leadership attention and OI decision making are also
important factors for implementing OI and are often closely related to OI roles and
responsibilities and business and OI strategy alignment.
The applications for professional practice would be to first define roles and
responsibilities for all key positions related to OI implementation. One role that seems to
be of significant importance is the search and evaluation function. These employees
typically have a graduate degree or medical degree and have experience doing biomedical
research. Formal training and research experience are important training and skills for the
scouts searching and identifying opportunities aligned with the leaders' business strategy.
In a pharmaceutical company, these staff can be recruited from within the company
because many of these organizations have many employees with PhDs and/or MDs.
Alternatively, leaders can recruit qualified staff from outside the company.
Also, encouraging staff in the OI positions to network, attend conferences and
meetings, and keep up to date with the literature will be helpful for all roles. The OI
implementation requires the participation of many stakeholders, therefore if each
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employee tries to expand their professional network, the network will be much larger.
The additive effect of each employee’s network expands the network reach, increasing
the chances of finding novel innovations.
Staying up to date with literature is imperative for all employees involved in the
OI process. The scientific literature was found to be a good place to find leads, subject
matter experts, and thought leaders in areas of interest. Pharmaceutical leaders should
lower the barriers to obtaining access to the literature with subscriptions to multiple
journals. Pharmaceutical leaders will benefit from implementing or improving upon these
strategies, which may have a largely positive effect on improving the odds of finding
novel innovations that can help maintain or achieve a competitive position in the
pharmaceutical industry.
Implications for Social Change
The results of this study will have direct implications for social change by helping
improve pharmaceutical leaders' efficiency in discovering and developing novel
therapeutics. OI activities result in a diverse network of collaborations with partners that
positively inﬂuence a company’s innovation success (Rauter et al., 2018). Pharmaceutical
leaders implementing the findings from this study may increase the efficiency of
discovering and developing novel therapeutics. An increase in the efficiency of
discovering and developing novel therapeutics may lead to cost-effective therapeutic
medicines that provide a better quality of life for many patients and in some cases may
save lives (Hunter et al., 2018). Pharmaceutical leaders implementing OI strategies will
improve their probabilities of discovering novel therapeutics more efficiently. This result
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of discovering and developing novel therapeutics more efficiently could lead to a
decrease in R&D costs with a resultant decreased cost of novel medicines.
Recommendations for Action
The findings from this study may be beneficial for pharmaceutical leaders
intending to implement OI strategies to discover and develop novel therapeutics. Based
on the findings of this study, defining the employees' roles and responsibilities, and
aligning their actions to implement the strategy should lead to success in implementing
OI.
Recommendation 1
Leaders need to create a clear strategy for the employees to advance their mission.
The participants (P1-P5) consistently acknowledged that the OI strategy was set forth by
the managements’ innovation strategy. de Oliveira et al. (2018) suggested the leaders'
strategy should clearly define the innovation-related strategic positioning. A defined
strategy is a critical success factor for implementing OI strategies (de Oliveira et al.,
2018). The leaders need to decide if they are going to search for radical innovations,
incrementally improve existing technology, or a combination. To be successful the
leaders will need to ensure they have enough absorptive capacity and that absorptive
capacity is managed throughout the innovation process. Managing knowledge and
technological competencies will improve a leader's chances of success.
Recommendation 2
After defining the business strategy, I would recommend defining the roles and
responsibilities of the employees in the organization particularly those employees
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involved in the OI process. One of the positions that participants indicated was key is the
search and evaluation function. The leaders of the team need to have a focused approach
to best utilize finite resources. Having a team skilled in identifying innovations that fit the
overall business strategy is a critical factor. All participants were well aware of
absorptive capacity and understood they were not able to accomplish everything.
The search and evaluation staff help to moderate the absorptive capacity. The
participants suggested that the company develops absorptive capacity through routines
and processes, especially information search practices, market monitoring procedures,
and risk management. Senior management prioritization and portfolio optimization were
often cited as drivers of their OI search strategy. I would recommend prioritizing the
goals and then using OI to explore and exploit those areas that will bolster and advance
the business strategy.
Recommendation 3
The third recommendation would be to explicate an OI strategy that would
achieve the business goals. Creating an OI strategy would provide direction for the staff
involved in the OI processes to ensure that resources are being used efficiently. Having
an OI strategy will be imperative to managing absorptive capacity. The P1-P5 suggested
that they consider the feasibility of doing a project internally before committing to
establishing external collaborations. Furthermore, senior management's explication of the
OI strategy will help to reduce the chances of not-invented-here syndrome (NIH). Senior
managers clearly stating the goals and justifying the strategy will help overcome NIH.
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Recommendation 4
My fourth recommendation is to assemble an alliance management team that is
skilled at managing employee relationships in collaborating organizations. Managers
should develop high internal capabilities to integrate external knowledge and enhance
potential absorptive capacity for future knowledge transfer and knowledge sharing
(Martinez et al., 2017). Once innovations are discovered and secured, assimilating those
innovations into the organization is important for the success of the project and to ensure
it is productive. One participant, P3 was directly involved with managing external
alliances and suggested alliance management is a critical function for OI projects to be
productive. P3 suggested keeping the staff focused on the patients waiting for the
medicines helps to reduce resistance between the organization's teams and focus their
efforts. After investing the time and resources into securing a collaboration, P3 suggested
managers of both organizations want to ensure the project is productive. One of the
reasons OI projects fail is because of the lack of project assimilation into the organization
resulting from uncertainty on the benefits of an alliance, a lack of information on
potential partners, and concern over sharing information with potential competitors
(Hewitt-Dundas et al., 2018).
Recommendations for Further Research
One of the limitations of this study is that it was a single case study in a large US
pharmaceutical company. To improve on this limitation researchers could use a multiple
case study for future research to explore strategies US pharmaceutical leaders use to
implement OI projects. One important aspect I noted was that the company in this single
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case study did not use crowdsourcing as one of its strategies. Crowdsourcing is a strategy
used by some pharmaceutical companies; therefore it would be a good reason for a
multiple case study because there may also be other differences between companies.
Furthermore, a researcher could also use the open innovation capability framework as a
lens to research implementation strategies in small and medium-sized companies that
have fewer resources.
Another limitation of my research was the participant sample size. Interviews
with five pharmaceutical R&D directors is a relatively small sample. The final limitation
of my study was the use of semistructured interviews as my primary data collection
method. Semistructured interview participants may not be equally articulate and
perceptive and thus may lead to less robust data.
Reflections
I started the doctoral journey to achieve the height of my education career and
give back to my chosen industry, the pharmaceutical industry. I chose to use a qualitative
approach because to me it was a new methodology, it was something new to expand my
knowledge. Having worked in biomedical research for over 36 years I was comfortable
with quantitative approaches. I was informed at the beginning of my doctoral journey as I
considered topics that most qualitative researchers are extroverts and quantitative
researchers tend to be introverts. Using a qualitative approach would be a stretch for me
since I am more introverted.
I found the qualitative approach to be more challenging but rewarding. As the
researcher is the instrument for collecting the data, I needed to ensure that my own biases
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did not creep into my decisions on data collection and analysis. Throughout the research,
I needed to reflect on my experience to guard against my personal biases that might have
an impact on my decisions. Furthermore, the research was performed at my employer and
therefore I needed to be more vigilant in guarding against my biases and protecting the
participants.
Conclusion
The purpose of this qualitative single case study was to explore strategies US
pharmaceutical company leaders used for successfully developing and implementing OI
R&D projects. I conducted semistructured interviews via synchronous computermediated interviews to explore the implementation experiences of five directors of R&D.
I used the OICF as a lens to explore the implementation of OI strategies and discovered
four themes. The four themes discovered associated with successfully developing and
implementing OI R&D projects were: (a) roles and responsibilities, (b) business and OI
strategy alignment, (c) leadership attention, and (d) OI decision-making. I triangulated
these themes with public websites of the organization in the single case study and
available literature and found the information discovered was in alignment with these
themes.
Pharmaceutical R&D directors may benefit from this study by modifying their
implementation strategies for OI projects. The modification of their strategy may lead to
greater success in the efficient implementation of OI projects and a reduction in R&D
costs. Pharmaceutical leaders implementing these strategies may have a beneficial impact
on their organization and society in general.
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Appendix A: Letter of Organizational Cooperation

08/24/2020
Dear John Maher,
Based on our e-mail communication and your description of the research
proposal, you are free to conduct the study entitled “Development and Implementation
Strategies for Open Innovation Pharmaceutical R&D Projects” As part of this study, you
are permitted to interview employees from my organization as part of the data collection
process. Individuals’ you contact are free to decline participation in your study and
should be afforded the opportunity to review their answers. Pfizer reserves the right to
withdraw permission to conduct the study at any time for any reason should
circumstances change.
I understand that the data collected will remain entirely confidential and may not
be provided to anyone outside of the student’s supervising faculty/staff without
permission from Pfizer and the Walden University IRB.

Sincerely,

Mikele D Simkins, DVM
Mikele Simkins, DVM, DACLAM

Director /Attending Veterinarian, Comparative Medicine
Pfizer Inc.
401 N. Middletown Rd.
Pearl River, NY 10965
Ph.: (845) 602-5748
Fax: (845) 602-4121
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Appendix B: Recruitment Letter
Doctoral Student seeks participants for an Interview study
The research Explores strategies US pharmaceutical company managers use for
developing and implementing open innovation pharmaceutical R&D projects. The
researcher is inviting participants who possess the knowledge to contribute relevant
information to the research. This interview is part of the doctoral study for John A. Maher
D.B.A. student at Walden University. Interviews will take place during the weeks of
XX/XX/XXXX to XX/XX/XXXX.
About the study:
• One 40-60-minute interview via WebEx, Skype, or Zoom that will be audio
recorded.
• After the interview you will review a summary of the interview transcript for
accuracy (~15-20 minutes) and follow up questions if applicable (5-10 minutes).
• You would receive a $25 Amazon gift card as a thank you.
• To protect your privacy, you will be assigned a pseudonym.
Volunteers must meet these requirements:
• Possess knowledge and experience with open innovation projects.
• Director level
To confidentially learn more about the study or request a consent form please
contact the researcher:
John Maher 845-XXX-XXXX
john.maher@waldenu.edu
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Appendix C: Consent Form
You are invited to take part in a research study that explores strategies US
pharmaceutical company managers use for developing and implementing open
innovation pharmaceutical R&D projects. The researcher is inviting participants who
possess the knowledge to contribute relevant information regarding strategies for
developing and implementing Open Innovation R&D projects to participate in the study.
I obtained your name/contact info via the guide. This form is part of a process called
“informed consent” to allow you to understand this study before deciding whether to take
part. This study is being conducted by a researcher named John A. Maher, who is a
doctoral student at Walden University.
Background Information:
The purpose of this study is to explore strategies US pharmaceutical company
leaders used for developing and implementing Open Innovation R&D projects. The
participants will comprise US pharmaceutical R&D directors in one pharmaceutical firm
that has successfully used Open Innovation strategies to develop and implement R&D
drug development projects.
Procedures:
If you agree to be in this study, you will be asked to:
•

Answer 10 interview questions via Webex or Skype (30 -60 minutes).

•

The interview will be recorded and kept confidential.

•

The time for the interview will be at your convenience.

•

You will review the interview transcript to confirm accuracy.
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•

Answer follow up questions if applicable.
Here are some sample questions:
1. What strategies did you use to implement an open innovation (OI) R&D
projects?
2. How did you identify new R&D projects to pursue using an OI strategy?
3. How did you decide which OI strategy to use for an OI R&D project?
4. What organizational issues did you consider when pursuing a given OI
R&D project?
5. What organizational capabilities did you consider when pursuing a given
OI R&D project?

Voluntary Nature of the Study:
This study is voluntary. You are free to accept or turn down the invitation. No one
will treat you differently if you decide not to participate in the study. If you decide to
participate in the study now, you can still change your mind later. You may stop at any
time.
Risks and Benefits of Being in the Study:
Participating in this type of study involves minimal risk and minor discomforts
that can be encountered in daily life such as being asked about your experience with OI
R&D projects. I anticipate that being in this study would not pose risk to your safety or
wellbeing.
My study findings could be significant for leaders in pharmaceutical firms
seeking to use OI strategies to improve their firms’ competitive positions in the market.
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Pharmaceutical leaders intending to implement an OI business model might be able to
use the implementation strategies that may be discovered through my research.
Pharmaceutical leaders may possibly use the prospective framework to lead a more
efficient and effective drug development process for reducing the cost of developing
drugs and increasing the resultant pharmaceuticals ‘efficacy
Payment:
For your participation in the interviews process and follow-up questions for this
study a $25 Amazon gift certificate will be provided after the completion of the study.
Privacy:
Reports coming out of this study will not share the identities of individual
participants. Details that might identify participants, such as the location of the study,
also will not be shared. The researcher will not use your personal information for any
purpose outside of this research project. Data will be kept secure by use a code for each
participant so their identity will be revealed. Furthermore, all files will be password
protected. Data will be kept for a period of at least 5 years, as required by the university
and then destroyed.
Contacts and Questions:
You may ask any questions you have now. Or if you have questions later, you
may contact the researcher via john.maher@waldenu.edu or 845-548-4074. If you want
to talk privately about your rights as a participant, you can call the Research Participant
Advocate at my university at 612-312-1210. Walden University’s approval number for
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this study is 09-14-20-0674379 and it expires on September 13, 2021. Please print or
save this consent form for your records.
Obtaining Your Consent
If you feel you understand the study well enough to decide, please indicate your
consent by replying to this email with the words, “I consent.”
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Appendix D: Interview Protocol/Questions
Primary Research Topic
Development and Implementation Strategies for Open Innovation Pharmaceutical R&D
Projects
The Overarching Research Question
What are the strategies that US pharmaceutical company leaders use to develop and
implement OI R&D projects?
Primary Research Goals of the Interview
The purpose of this interview is to explore the organizational factors and
capabilities that are critical to employing open innovation strategies for research and
development projects. The two most important questions in the exploration are 1.) How is
the decision to use an open innovation strategy for a single R&D project reached? 2.)
How is the decision to employ any particular strategy reached?
Initial Probe Questions
1) What is your title?
2) What is your role in the organization?
3) In your own words, what is open innovation?
Targeted Interview Questions
1) What strategies did you use to implement an OI business model for R&D
projects?
2) How did you identify new R&D projects to pursue using an OI strategy?
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3) How did you decide which OI strategy to use for an OI R&D project?
4) What organizational issues did you consider when pursuing a given OI
R&D project?
5) What organizational capabilities did you consider when pursuing a given
OI R&D project?
6) How did you decide which capabilities are important to implement an OI
R&D project?
7) How did you decide which employees should participate in the
implementation of OI R&D projects?
8) If your organizational culture supports OI R&D, describe how your
culture supports the implementation of OI R&D projects?
9) [If the organizational culture supports OI] Describe the strategies used to
align the organizational structure to support OI R&D projects?
10) What else can you tell me you did to enhance OI strategies?
Targeted Follow-Up Questions
If time allows targeted questions will be follow up Why questions to discover
underlying reason for a decision if not already clear.
Targeted Wrap-Up Questions
If time allows targeted questions will be follow up Why questions to discover
underlying reason for a decision if not already clear.
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Interview Closure
I will thank the interviewee(s) for his or her valuable contribution and promptly record
my reflections of each interview process. I will also explain the follow up member
checking process.

